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Two specific goals were addressed for this dissertation. First to investigate
and identify the mechanistic profile of ketoconazole (KT)-induced hepatotoxicity
by utilizingin vivoandin vitroapproaches determining the mechanism of action
for the hepatotoxicity incurred. To date, there has not been a mechanistic
determination of the hepatotoxicity associated with KTin vivo.This dissertation
evaluates the possible metabolic bioactivation of KT by cytochrome-P450 (CYP)
or flavin-containing monooxygenases (FMO) resulting in covalent binding with
hepatic macromolecules. The hypothesis of this study was to reveal whether
covalent binding by the parent compound, KT, and/or reactive metabolites
Redacted for privacyproduces hepatic damage associated with increased serum alanine
aminotransaminase (ALT) release and decreased hepatic glutathione (GSH). The
first objective was determination ofin vivocovalent binding in a dose-time
response comparison in Sprague-Dawley (SD) rat ALT and GSH levels. Increased
ALT and reduced hepatic GSH levels occurred. The second objective was anin
vitro comparison of covalent binding with GSH levels utilizing SD microsomal
protein with incubations of KT. Covalent binding decreased with added GSH to
microsomal incubations. Thirdly, correlatein vivowithinvitro findings. Covalent
binding of KTin vivoandinvitro occurred with increased doses and time. The
final objective was to determine the bioactivation pathway utilizing heat
inactivation and no NADPHinvitro. Covalent binding of KT decreased in the
absence of NADPH and deactivation of FMO.
The second goal was to determine and quantitateinvitro the presence of
FMO isozymes in microsomes of the human intestinal duodenum, jejunum, ileum,
and colon as well as the Caco-2 (HTB-37), epithelial intestinal (CCL-241) and
colon (CRL 1790) cell lines. The presence of FMO could result in a first-pass effect
decreasing the bioavailability of soft nucleophiles or a toxicity effect due to
inhibition or modulation of the enzyme from co-administration. To date, this is the
first evaluation of FMO isoforms in human intestine and cell lines. Western blot
techniques were utilized for detection of human FMO1, FMO3, and FMO5 using
human FMO-expressed recombinant cDNA from a baculovirus system.Quantifiable detection of FMO 1 was verifiable for the jejunum, ileum, colon, and
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CHAPTER 1: INTRODUCTION
1.1. BACKGROUND
Exogenous compounds, such as pharmacologically active drugs, are
foreign to the body and upon entrance can be chemically altered by enzymatic
metabolizing components present within the physiological system. Oral
administration of therapeutic compounds has become increasingly popular versus
the inconvenience and elevated cost of an intravenous (i.v.) dose requiring
administration by a doctor or nurse. The absorption, bioavailability, distribution,
and elimination of the compound determine the onset and duration of action.
Principle sites for drug metabolism occur in the small intestinal
mucosa and the liver due to a high concentration of metabolic enzymes that
conduct phase I and phase II biochemical reactions, such as oxidation, reduction,
hydrolysis, and conjugation. Metabolism of an orally administered compound can
result in reduced bioavailability or toxicity by either altering the metabolic profile
or changing the rate of elimination. In humans, gender, genetics, other drug
interactions by inhibition, induction, or modulation of enzymes, as well as
environmental factors can alter the pharmacokinetics and/or pharmacodynamics of
an orally administered drug. Other factors to consider for altered kinetics or2
therapeutic effects are: drug instability in the gastrointestinal tract (GI), inadequate
release from the dosage form, poor intestinal permeability, delayed or erratic rate
of absorption, or a first-pass effect.
The GI tract, referred to as the alimentary tract or canal, is divided
into 11 anatomical regions and is approximately 435 cm long. This canal is
controlled by the enteric nervous and hormonal systems (Guyton 1991) and
functions in absorption, digestion, and elimination of residual waste (Marieb
2001). The alimentary tract continually supplies the body with water, electrolytes,
and nutrients by movement of food, secretion of digestive juices and digestion of
food, absorption of digestive products, and the circulation of blood (Guyton 1991).
Several of the enzymes found in the liver are detected in the mucosal
epithelium of the GI tract. These include cytochrome P450 (CYP) (Zhang,et al.
1999), glucuronosyl transferases, sulfotransferases, N-acetyl transferase,
glutathione S-transferases, esterases, epoxide hydrolase, and alcohol
dehydrogenase (Thummel,et al.1997), amylases, peptidases, reductases,
phosphatases, esterases (Renwick 1982), and Flavin-containing monooxygenases
(FMO) (Larsen-Su and Williams 1996, Yeung,et al.2000). Enzymes conducting
metabolic reactions in the small intestine are as follows: CYP1A1, 2D6, 3A4
(Zhang,etal. 1999), monoamine oxidation, hydroxylation, dealkylation,
desulfuration, reduction, hydrolysis, glucuronidation, sulfation, N-acetylation (Ilett
and Davies 1982), 0-methylation and glutathione (Caldwell and Marsh 1982).
Table 1 indicates the detected enzymes found in the small intestine.Table 1. Phase I enzymes and isozymes, and phase II reactions with cofactors/
enzymes detected in small intestine.
Phase I enzymes Isozymes
CYP IAI, 1A2, 2B, 2C (Oda and Kharasch 2001),
2D6, 3A4 (Zhang,etal.999)
FMO FMO 1 (Yeung,et al.2000)
Alcohol dehydrogenase (Klaassen 1996)
Prostaglandin H synthase
Phase II reactions Cofactors and enzymes, respectively
glucuronidation uridine diphosphate (UDP)-glucuronic acid,
UDP-glucuronosyltransferases (Ilett and Davies 1982)
sulfation 3 '-phosphoadesosine-S' phosphosulfate (PAPS)
sulfotransferases (Ilett and Davies 1982)
N-acetylation acetyl-coenzyme A
N-acetyl transferases (Ilett and Davies 1982)
O-methylation S-adenosylmethionine (SAM)
phenol-O-methyltranferase (POMT)
catechol-O-methyltransferase (COMT) (Caidwell and
Marsh 1982)
glutathione (GSH) conjugation glutathione, glutathione synthetase (CaIdwell and Marsh
1982)
The primary site of absorption for orally administered drugs is across
the epithelial mucosa of the small intestine due to three factors: an extensive
absorptive area of approximately 600 m2 (Campbell 1993), lipophilic permeability,
and high perfusion, total blood flow of 1.0 to 1.5 L/min (Rowland and Tozer
1995). Absorption in the gut wall has been stated to be highest in the duodenum
and jejunum of the small intestine due to a folding of the mucosal epithelial lining,
known as the plica, and the villi-microvilli appendages, increasing the surface
area. The plica folds become obscured in the ileum and colon, resulting in a'Al
decreased surface area in these regions. Until recently, intestinal absorption had
been considered to occur without metabolic alteration; therefore, little attention
was given to differentiating between possible metabolism occurring in the GI wall
versus the liver (llett and Davies 1982).
During intestinal absorption and metabolism, a pre-systemic
clearance resulting in a first-pass effect decreases the systemic availability of a
compound (Ilett,etal. 1990). The enzymatic first-pass effect is responsible for
altering or diminishing bioavailability and therapeutic effects of the fraction of a
drug absorbed from the oral dose (F). Many of the metabolizing intestinal
enzymes detected in the mucosal epithelium conduct biotransformation of orally
administered drugs (Thummel,et al.1997). For example, FMO has been detected
in the small intestine (Yeung,et al.2000), but little is known of the presence of or
oxidative metabolism performed by individual FMO isoforms, specifically in the
duodenum or jejunum. Therefore, the concept that metabolic alteration within the
intestinal wall does not occur after drug absorption is misleading. Now, the first-
pass effect consists of intestinal and liver metabolism.
1.2. ABSORPTION, BIOAVAILABILITY, AND KINETICS OF
EXTRA VASCULAR (e.v.) DOSING
With extravascular(e.v.)dosing, the absorption phase is a
prerequisite for bioavailability and therapeutic activity. Bioavailability refers to
both the rate (ka) and extent of the dose-administered that reaches the systemichi
system, and is defined by the area under the blood concentration-time curve
(AUC). The fraction of the dose that is administered,F,that reaches the systemic
circulation intact is determined by the ratio of the AUCs after extra- and intra-
vascular drug administration.Fis the measure of the extent of first-pass
metabolism (Pond and Tozer 1984). At the peak of absorption, when drug
absorption = drug elimination from the systemic system, the plasma concentration
is at a maximum (Cmax), and the time that it took to reach this peak is referred toas
tmax(Rowland and Tozer 1995). Bioavailability comparisons are referred to as
absolute and relative bioavailabilities. Absolute bioavailability is a comparison of
thee.v. dose and an i. v. bolus dose, whereas relative bioavailabilities indicate the
comparison of ane.v. dose with anothere. v.dosage form, a different route, or
different conditions (Winter 1994).
1.3. METABOLISM
1.3.1 First-pass effect
In recent findings, occurrence of first-pass metabolism and a
reduction in concentration of a xenobiotic in the systemic system might be
occurring in the small intestine (Fromm 1996, Holtbecker,etat. 1996, Paine,etat.
1996, Doherty and Charman 2002). Also, the first-pass effect may be greater
through intestinal metabolism than the liver (Fromm 1996, Hoitbecker,etat.
1996). The first-pass effect is characterized by the pre-systemic removal of a drug,
resulting in reduced bioavailability after oral administration. First-pass metabolismis affected by such factors as pH, unabsorbed nutrients and xenobiotics (chelation
interactions), intestinal microflora (Renwick 1982), age, gender, disease states,
enzyme induction and inhibition, and genetic polymorphism (Tam 1993). Drugs
that undergo extensive first-pass metabolism often exhibit considerable variation
in systemic bioavailability, due to interindividual therapeuticresponses
represented in the plasma concentration after ane. v.administration (Pond and
Tozer 1984). Determining the enzyme presence and activity could aid in avoiding
these problems.
Comparing bothe.v.and i.v. administration, it is possible to
determine the extent the drug is being removed before entrance into the systemic
system, but differentiating the site of metabolism between the bacterial flora of the
gut lumen, the gut wall, and the liver is difficult (Renwick and George 1989). Due
to hepatic metabolism contributions to the first-pass effect, attempts to by-pass the
liver by other routes, such as sublingual or rectal have been effective in increasing
the bioavailability of drugs (Caidwell and Marsh 1982). The pre-systemic
clearance becomes important when a significant amount of ane.v.dose is
eliminated during the first passage of a drug. The availability of a drug is
determined by the product of the fractions of the drug entering the tissue that are
not lost in each successive tissue (Pond and Tozer 1984). F is expressed as:Forai =
FG * FL * FwhereFG, FL, Fare the fraction of the drug that has survived the GI
tract, the liver, and the lung, respectively (Renwick and George 1989).7
Another variable is metabolism conducted in the gut by the vast
number of organisms, approximately 1010 per gram of gut contents. In humans
most metabolic organisms are present in the lower bowel due to their anaerobic
characteristic. Nearly all of the microbial metabolizing activity is found in the
cecum (ileum connection to colon) and colon resulting in azo- and nitro-reduction,
113-glucuronidase cyclamate hydrolysis, and sulfoxide reduction. Xenobiotics will
reach the gut flora either by incomplete absorption from e. v. administration, biliary
excretion, or secretion into the gut lumen from a systemic dose (Renwick and
George 1989).
1.3.2. DetoxicatonlBioactivationlTherapeutic window
Plasma concentrations of a drug must correlate with both the intensity
and probability of therapeutic or toxic effects. Therapeutic failurecan arise if the
drug has a narrow therapeutic window and variability in the pharmacokinetics,
erratic absorption, and non-compliance by the patient or if the patient is at risk due
to genetic factors, disease, or multiple drug therapy (Rowland and Tozer 1995).
Metabolic toxicity from the parent compound and/or the metabolite(s)
formation is dependent upon the Cmaxof the plasma concentrations achieved, the
duration of the exposure to the toxicant above the threshold of the minimum
toxicity level (MTL), or the accumulation of the toxicant within the systemic
system. Metabolic activation of a xenobiotic to a bioactivated intermediate can
alter the cellular function resulting in cellular necrosis and cell death by covalentlybinding and altering cellular macromolecules leading to enzyme inactivation,
altered functions of structural proteins or transcription, disruption of intracellular
calcium homeostasis, loss of cellular membrane integrity due to lipid peroxidation
or apoptosis (Pohi,etal. 1996). Utilizing pharmacokinetic parameters of
absorption, metabolism and bioavailability, distribution, and elimination aid in
predictable determinations of plasma concentrations within the systemic system
(Cashman,etal. 1996). Determining the relationship of inter- and intra-individual
metabolic alterations and how these relationships are changed by xenobiotic
interaction is essential for future prediction of drug bioavailability (Hodgson,et al.
1995).
1.3.3. Phase I and Phase II Enzymes
There are two major group classifications for drug metabolizing
enzymes, phase I and phase II. Phase I enzymes are classified as a non-synthetic
reaction. They modify a drug by either introducing or exposing a polar functional
group of the xenobiotic through oxidation, reduction, or hydrolysis, producing a
metabolite rendering the compound active, inactive, or bioactive. The two major
phase I metabolic enzyme systems that conduct oxidative metabolism are CYP and
FMO. These enzymes are present in the membrane of the endoplasmic reticulum.
The phase II enzymes conduct a conjugation of the parent compound and/or its
phase I formed metabolite to a secondary metabolite resulting in increased
polarity. Most therapeutic drugs are lipophilic, which undergo phase I and/orphase II conjugation to increase the polarity of the metabolite in comparison with
the parent compound escalating the excretability (Iyer and Sinz 1999).
Phase I metabolism creates metabolite(s) that may not reach the
systemic system resulting in reduced bioavailability and efficacy. The CYP
superfamily is a set of metabolizing phase I monooxygenase microsomal
hemoproteins ubiquitous in nature (Cashman, et al. 1996). The major subfamilies
of CYP enzymes metabolizing drugs are 1A2, 2C, 2D6, 2E1, and 3A (Doherty and
Charman 2002). The following table, Table 2, presents the major CYP isoforms
and the percentage of drugs each isoform will metabolize.
Table 2. An approximate proportion of all drugs metabolized by major CYP
metabolizing enzymes.
CYP Isozymes %Proportion of CYP
metabolism of drugs
CYP1A2 2
CYP2C 16
CYP2D6 25
CYP2E1 2
CYP3A 55
The subfamily CYP3A is estimated to participate in 55% of the
oxidative biotransformation of drugs. There are four members of the CYP3A
subfamily found and characterized in humans. In the intestine and liver, the10
CYP3A4 is the most abundant form, but CYP3A5 has been found to represent
greater than 50% of the total CYP3A in some individuals (Thummel,et al.1997).
CYP requires the flavoprotein NADPH-cytochrome P450 reductase for metabolic
activity (Klaassen 1996).
CYP REACTION:
NADPH-CYP reductase
XII (substrate)+02+NADPH + H' Product (X) + H20 + NADP
CYP has been found to conduct pre-systemic metabolism in both the
liver and the mucosa of the small intestine resulting ina first-pass effect
(Cashman,et al.1996). The CYP isozymes 1A2, 2C9, 2C19 2D6, and 3A4 are
implicated most often in first-pass elimination (Thummel,et al.1997). Some of
the CYP3A4 substrates undergoing metabolic extraction by the gut wallare
cyclosporine, midazolam, nifedipine, verapamil (Thummel,et al.1997), and
methadone (Oda and Kharasch 2001). In the intestine, the total intestinal CYP3A4
enzyme protein concentration has been reported to be from 23 pmol/mg of
intestinal microsomal protein (Thummel,et al.1997) to as high as 70 nmol,
predominantly in the jejunum (Hall,et al.1999).
FMOs are also a phase I oxidative monooxygenase. FMO and CYP
have often shown activity toward many of the same substrates, but generally FMO
enzymes produce different metabolites with fewer bioactivations than CYP, which
will be reviewed in the next section (Larsen-Su and Williams 1996).11
1.4. HISTORY OF FLA YIN-CONTAINING MONOOXYGENASES (FMO)
1.4.1. Characteristics of FMO
Elucidation of the structure for the specificity of mammalian drug-
metabolizing enzymes has made considerable progress in the past decade, due to
x-ray crystal structures. In comparative analysis of the different FMOs amongst
species, important leads have been determined for structure-function analysis
(Halpert,et al.1998). FMO, classified as EC1.14.13.8, a non-heme microsomal
FAD-containing enzymatic system (Ziegler 1988), was initially purified from hog
liver in the early 1970's. The FMO enzyme has been suggested to be anchored in
the endoplasmic reticulum at the hydrophobicNH2and COOH termini (Dolphin,
et al.1991). FMO is NADPH and oxygen-dependent catalyzing soft nucleophilic
compounds with an electron rich center (Ziegler 1988) in drugs, pesticides, and
plant products (Halpert,et al.1998, Park,et al.2002) containing nitrogen, sulfur,
(Ziegler 1980, Park,et al.2002) phosphorus (Phillips,et al.1995, Park,et al.
2002), or selenium (Phillips,et al.1995, Halpert,et al.1998).
The FMO biotransformation can either detoxify a lipophilic
compound to a hydrophilic compound for excretion or undergo "bioactivation"
resulting in a metabolite that can cause histological changes, carcinogenesis,
mutagenesis, or teratogenesis. FMOs are known to produce a less reactive
metabolite or completely detoxify a xenobiotic (Ziegler 1990), but can potentially
be converted to a toxic intermediate by binding to DNA, RNA, and protein with12
detrimental consequences (Atta-Asafo-Adjei,etal. 1993). For example, the
oxidation of a thiocarbamide results in a sulfenic acid metabolite, which is a highly
reactive electrophile (Poulson,etal. 1979, Krieter,etal. 1984, Decker and Doerge
1991) that can bind to macromolecules in the lung and the liver (Poulson,etal.
1979, Krieter,etal. 1984, Decker and Doerge 1991) or produce chemical species
that inactive CYP (Poulson,etal. 1979, Krieter,etal. 1984, Decker and Doerge
1991)
1.4.2. Mechanism of FMO
FMOs are present in the cell in the oxygen-activated form and
oxygenate soft-nucleophilic xenobiotics. The soft nucleophile can be oxidized
when accessible by the enzyme-bound peroxy-flavin intermediate. Other oxidases
and monooxygenases are not readily present in the oxygen-activated state, thus
FMO is unique in its classification (Ziegler 1990). NADPH, the electron source,
binds and reduces the flavin in the first step of the FMO catalytic cycle as shown
in Figure 1. In steps two and three, dioxygen reacting with the reduced flavin
creates a stable 4a-hydroperoxyflavin intermediate, in the absence of an
oxygenatable substrate (Hines,etat. 1994). Transference of the oxygen from the
hydroperoxyflavin to a substrate occurs in steps 4 and 5, without the formation of
an intermediate during the oxygen transfer. The lack of an intermediate formation
indicates activation of the substrate is not required. In steps six and seven, a
release of the NADP occurs. Because steps six and seven occur after substrate13
oxygen addition and release of the oxygenated product, the mechanism predicts
that at saturation all substrates are oxidized at the same velocity (Ziegler 1988).
The energy required for catalysis is already present in the enzyme, thereforea
structured enzyme and substrate fit is not required as with other enzymes (Atta-
Asafo-Adjei,et al.1993). The result is a catalyzation with efficiency. CYP can
oxidize the same nucleophilic heteroatoms and create the same products as an
FMO heteroatom oxidation, but CYP is less efficient (Cashman,et al.1996).
FMO reaction:YH +02 + NADPH + H YOH + 1120 + NADP
(Where Ysubstrate)14
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Figure 1: Schematic of the FMO metabolic cycle. Indicated is the substrate binding
to the 4a-hydroperoxyflavin (active form) transferring the oxygen to the substrate
(N) and reconfiguration to the active form by addition of NADPH and oxygen
(Rettie and Fisher 1999).15
1.4.3. FMO Isozymes
The FMO family contains five structurally related isoforms encoded
by its own gene (Cashman 2002). The FMO gene encoding for all five of the
isoforms is located on the chromosome lq (14). FMO1 FMO5 contain one non-
coding exon and eight coding exons. The sequence and location of the binding
domains of the FAD and NADPH motif are conserved in the mammalian isoforms
FMO1, 2, 3 and 4 (Ziegler 1990). At the putative active site located between
residues 9 14, FAD is non-covalently bound. The NADPH putative binding site
is located between residues 19 1-196 (Phillips,et al.1995). Near the N-terminal
region are 2 glycine-rich regions in FMO1 FMOS, with inherent NADPH and
FAD binding (Dolphin 1992). The highest conserved areas are found within four
regions producing only 57% of the length of the polypeptide. They are from 1
230, 320 340, 350 370, and 455 to 500 (Phillips,et al.1995). FMO1 FMOS
contain a primary sequence that is 50-55% identical with each other (Ziegler 1990)
and orthologs of various species of sequence identity is approximately 8 1-89%
(Hines,et al.1994). FMOI FMO5 are encoded for a functionally active protein,
but FMO6 is not (Cashman 2002). Each of the first five mammalian FMOs
exhibit distinct, but broad substrate specificity overlapping other FMO family
members as well as with CYP isoforms (Hines,et al.2002). Due to tissue
specificity and amino acid sequencing, mammalian orthologs of FMO are assigned
with amino acid identities greater than 80%. The following diagram, Figure 2, is a
representation of pig FMO1 amino acid sequences. FMOs 1, 2, 3, 4 and 5 are 53216
to 558 amino acids long (Dolphin,et al.1991, Phillips,et al.1995, Gasser 1996)
on 9 exons (Krueger, Williams,et al.2002), and 8 introns (Cashman 1995) and
have a molecular mass of approximately 60 kDa to 63 kDa, with FMO 4 being the
longest and heaviest. The guidelines for a systematic nomenclature for mammalian
FMO followed the CYP identification procedure andwere based upon divergent
evolutionary relationships (Cashman 1995).
(Acetyl)N
l94Ser
l2OAsn-X-Ser/Thr
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Figure 2: Schematic of the pig FMO1 amino acidsequence. The shaded bar
region is the lipophilic C-terminus region of the protein (Cashman 1995).
FMO1 mRNA has been detected in the human fetal liver and is 86%
identical to the porcine liver (Dolphin,etal.1991, Gasser 1996), as well as the
human adult kidney and skin, but not in the adult liver. Reportedly, FMO 1 is
expressed in the human adult kidney and in fetal liver tissue at concentrations of
47 ± 9 pmol/mg of micro somal protein and 8 ± 5 pmol/mg of microsomal protein,17
respectively (Hines, et at. 2002). The lack of detection of FMO1 in the human
adult liver, <1 pmollmg of protein (Yeung, et at. 2000), is in contrast to other
mammals. FMO 1 is the major form of the FMO enzyme in an adult pigor rabbit
liver (Phillips, et at. 1995). FMO3, the primary form found in abundance in the
human adult liver (Lomri, et at. 1992, Yeung, et at. 2000), has been detected at
protein levels of 60 ± 43 pmol/mg of microsomal protein (Hines, et at. 2002).
Due to the detection of FMO 1 in the human fetal liver and minimal
detection in the human adult liver, there appears to be a developmental change
from FMO1 to FMO3. A temporal switch sometime after birth in hepatic FMO
expression occurs, as found in CYP fetal expression (Yang, et at. 1994). During
the first few days of birth, irrespective of gestational age, an increase in the
CYP3A4 isoform from the CYP3A7 occurs during the early neonatal period
suggesting a transition (Lacroix, et at. 1997). The FMO3 gene is also increased
with developmental regulation, thus FMO1 and FMO3 are tissue-specific and
regulatory. On the basis of tissue patterns and developmental expression, FMO
isoforms such as FMO 1 and FMO3 can be distinguished (Dolphin 1996). The
FMO2, FMO4, and FMO5 are expressed in the human adult lung and liver
(Dolphin, et al. 1991, Phillips, et al. 1995, Yeung, etal. 2000). FMO5 is also
expressed in the kidney (Yeung, et at. 2000).
The sixth FMO-like gene was located and identified between the
FMO2 and FMO3 genes. The motif of this isoform is 418 amino acids in length.
An FMO full-length active protein of 539 amino acids contains both the FAD and":3
NADPH binding domains. FMO2 has displayed, in previous studies,a truncated
version reduced by 64 amino acids that result in an inactive protein; therefore it is
probable FMO6 would not exhibit oxidative monooxygenase activity. To date,
FMO6 does not indicate the production of a protein and is being considereda
pseudogene that is the product of an evolutionary event due to eukaryotic splicing
events (Hines,et al.2002). The following table, Table 3, depicts the isozyme and
its location within the human body.
Table 3: Individual FMO isozymes present in human tissue.
FMO Tissue identification and distribution
Isozymes
FMO 1 Adult kidney (Hines, et al. 2002), fetal liver (Dolphin, et at. 1991, Gasser 1996),
intestine (Yeung, et al. 2000), esophagus and nasal mucosa (Cashman and
Zhang 2002)
FMO2 Lung (Dolphin, etal. 1991, Phillips, etal. 1995)
F11v103 Liver (Lomri, etal. 1992, Yeung, etal. 2000, Hines and McCarver 2002), brain
(Cashman and Zhang 2002)
FMO4 Lung, liver (Dolphin, et at. 1991, Phillips, et al. 1995, Yeung, et al. 2000), brain
(Cashman and Zhang 2002)
FMO5 Lung (Dolphin 1998), kidney (Yeung, et al. 2000), brain (Cashman and Zhang
2002)
F1v106 Determined gene location (Hines, etal. 2002)
1.4.4. FMO Substrate specificity
Soft nucleophiles such as: secondary and tertiary alkylamines and
arylamines, hydrazines, thiocarbamides, thioamides, sulfides, disulfides, and thiols
are substrates for FMO oxidation (Ziegler 1990, Hines,et al.1994). Nitrogen-19
containing organic compounds such as tertiary aminesare good substrates for
FMO catalyzation producing an N-oxide. Secondary aminesare metabolized to a
hydroxylamine and/or a nitrone, primary amines toa hydroxylamine and/or oxime,
and a hydrazine to a hydrozone (Ziegler 1984). Primary arylamines, when N-
methylated by S-adenosylmethione (SAM), a phase II enzymatic cofactor required
for methylation, are found to be good substrates for an FMO reaction. Arylamines
such as N-methylarylamines undergo oxidation by FMOs toan intermediate
hydroxylamine. Further metabolic alteration produce a nitrone and thena primary
aryihydroxylamine (Ziegler 1990). FMOs are known for detoxification of organic
sulfurs and alkaloids, but activation of mercaptopyrimidines and thiocarbamides
result in chemical toxicity (Hines,et al.1994).
Regeneration of a parent compound after reduction can result in a
"futile cycle" (Decker and Doerge 1991). Conjugation by reduced glutathione
(GSH), a phase II oxidative scavenger, can deactivate a bioactive metabolite. With
a cyclic regeneration of the parent compound a depletion of GSH within the tissue
can occur (Krieter,et al.1984). For example, FMO-catalyzes oxidation of
thioureas to a reactive metabolite, then the parent compound is regeneratedupon
reduction and established is a futile cycle by oxidation of cellular thiols by
NADPH and oxygen that can deplete GSH within the tissues (Hines,et al.1994).
+
NADPH + H
GSH Reaction: GSSG 2 GSH
Glutathione reductase20
The following drugs are substrates for FMO oxidation: imipramine, a
tricyclicantidepressant tertiary amine (Adali,et al.1999) and an FMO 1 substrate
(Wyatt,et al.1998); chlorpromazine, an antipsychotic tertiary amine drug and
FMO1 substrate (Adali,et al.1999); methimazole, antithyroid drug (Wyatt,et al.
1998) and FMOI/FMO3 substrate (Cashman 2000); and ailbendazole, a parasitic
drug and FMO1 substrate (Villaverde,et al.1995).
1.4.5. FMO Polymorphisms
Polymorphic expression of either phase I or phase II enzymes could
have an effect on the efficacy or toxicity of therapeutic drugs. Expression of
variable alleles resulting in enhanced or reduced metabolic capacitiesare
associated with genetic predisposition. FMO2 and FMO3, the major adult isoforms
in the lung and liver, respectively, have been found to carry polymorphisms. The
mutations detected are homozygous amber mutations (premature termination),
substitutions, deletions, and truncation mutations resulting in metabolic alterations.
The expression of protein from pseudogene FMO6 isoform has not been
demonstrated (Krueger, Martin,et al.2002) and to date, a polymorphism in FMO 1
has not been determined.
Polymorphism effects are variable between populations, which may
indicate a specific mutant genotype (Forrest,et al.2001). Interindividual variation
of polymorphic effects in metabolism has been observed, which adds to the21
complexity for determination of tissue-specific FMO expression. These variations
with other drug metabolizing enzymes are influenced by both environmental and
genetic factors, but environmental factors do not appear to havea profound affect
on FMO expression (Whetstine,et al.2000).
Genetic polymorphisms have been characterized in two of the six
FMO gene families, FMO2 and FMO3 (Krueger, Williams,et al.2002). Human
FMO3 polymorphisms appear to be non-randomly distributed withina population.
Trimethylaminuria (TMAU), an FMO3 polymorphic disorder, isa biochemical
failure to oxidize trimethylamine (TMA) to the N-oxide (TMAO). TMAU is
characterized by the excretion of an excessive amount of a tertiary aliphatic amine
in the urine, sweat, breath and other bodily excretions (Mitchell and Smith 2001,
Cashman 2002).
TMA has been shown to be rapidly absorbed from the human GI
tract. TMA is metabolized in the gut to the major metabolite TMAO and is cleared
by hepatic first-pass metabolism. The metabolism of TMAappears to be mediated
by the FMO system (EC 1.14.13.8) and influenced by liver disease (A1-Waiz,et al.
1987, Lang,et al.1998). TMAO stabilizes proteins and offsets the destabilizing
effects of urea (Zou,et al.2000). TMA arises from dietary choline, contained in
egg yolks, organ meats, fish, legumes and whole soybeans (Treacy,et al.1998),
carnitine. TMAO may also be formed by intestinal bacterial degradation of
choline and lecithin (Cashman,et al.1997, Lang,et al.1998). A diet of brassica
vegetables, such as brussel sprouts, broccoli, cabbage, and cauliflower can alter the22
urinary ratio of TMAO to TMA, resulting in a transient TMAU condition due to an
inhibition effect of human FMO3 by acid condensation products from the presence
of indole-3-carbinol (1-3-C) in these vegetables (Cashman, Xiong, Lin,et al.
1999). Patients with FMO3 mutations may exhibit an alteration in detoxification or
possible bioactivation of drugs dependent upon hepatic FMO3 as a major route of
metabolism (Krueger, Williams,et al.2002), such as tricyclic antidepressants or
nicotine (Mitchell and Smith 2001). The presence of TMA in human urine was
reported for the first time in 1856 (Al-Waiz,et al.1987), but historically anecdotal
descriptions of individuals with fish malodor syndrome have been recorded from
1000 BC. Table 4 shows the research and clinical observations of TMA since the
first clinical description in 1970 (Mitchell and Smith 2001).23
Table 4: Observation dates and research regarding trimethylaminuria (TMAU)
since the first clinical observation.
Period Clinical observation since 1970
1970 First description- "fish odor syndrome" associated
with excessive TMA excretion and Turner's syndrome
1970-1985Description of isolated and sporadic cases
1980 Recognition of "tainted egg" syndrome breed of
chicken with dysfunctional N-oxidation
1980-1990Clinical and biochemical case studies from several
countries characterization of a human genetic
polymorphism of TMA N- oxidation
1990s Molecular genetics of FMO and recognition of
candidate mutations for the fish malodor syndrome
1.5. METABOLIC ALTERATIONS
1.5.1 Concomitant administration of FMO substrates
Metabolic alterations may occur with concomitant administration of
CYP/FMO substrates. In one study with human liver microsomes, chlorpromazine
and irnipramine were found to increase FMO3 metabolic activation of
methimazole. The findings indicated the manner and extent of modulation are a
function of not only the FMO isoform and effector molecule, but also the
concentration of the substrate (Adali, et al. 1999).
Another study using FMO1 and FMO2 rabbit and pig, imipramine
was found to inhibit and activate the same FMO isoform, which was dependent24
upon the concentration of methimazole. In rabbit, imipramine modulated FMO1
and FMO2 and increased the metabolism of methimazole. With pig FMO1,
imipramine inhibited the activity of methimazole and demonstrated competitive
inhibition. Because rabbit and pig FMO1 orthologs are 87% identical in
sequencing, the differences between the responses of pig and rabbit FMO 1 could
provide a starting point for investigation to determine the interaction of modulators
with the FMO isoforms (Wyatt,et al.1998).
In anin vitrostudy, methimazole inhibited rat intestinal microsomal
FMO metabolism of albendazole (Villaverde,et al.1995). When methimazole was
added to the microsomal preparation containing albendazole, inhibition of the
metabolism of albendazole was approximately 50-60%. The sulfoxidation
inhibition by methimazole supports the theory that FMO may be involved in
intestinal metabolism of albendazole (Viflaverde,etal.1995).
1.5.2. Modulation of FMO: inhibition/induction
Co-administration of food or drink can interfere or alter the
metabolism, of a xenobiotic by altering the amount and/or activity of drug
metabolizing enzymes. Phase I reactions appear to be more susceptible to the
effects of food or drink than phase II reactions (Walter-Sack and Klotz 1996).
An example is the concomitant administration of grapefruit juice andsome
medications, such as felodipine (Lown,et al.1997), whereas a change in
metabolism occurs (Fuhr,et al.1993). Grapefruit juice has been shown to inhibit25
the presystemic or first-pass elimination of certain drugs, suchas felodipine,
nifedipine, verapamil, and midazolam resulting in an increase inserum
concentrations (Miniscalco,et al.1992). CYP appears to be predominantly
affected by grapefruit juice administration, particularly CYP3A4. Even though
CYP3A4 is expressed in both the liver and the intestine, studies suggest grapefruit
juice appears to be most effective at the intestinal level (Maskalyk 2002). For
example, with co-administration of grapefruit juice and felodipine an increase in
plasma concentrations of felodipine were detected in the systemic system. The
grapefruit effect was isolated to CYP3A4 activity in the small intestine, whereas a
reduction of CYP3A4 activity did not occur in the colonic mucosaor the liver. The
bioavailability of felodipine is 20%, but with acute (one glass of grapefruit juice)
and chronic (one glass of grapefruit juice 3 times a day for 5 days) administration
of grapefruit juice, the plasma concentrations of felodipine doubled and tripled,
respectively (Lown,et al.1997).
St. John's Wort, an herbal product for the treatment of depression,
has been found to induce both intestinal and hepatic CYP3A4 activity. In two
studies with concomitant use of St. John's wort and simvastatin (a drug used to
lower plasma lipoprotein levels) a decrease in plasma concentrations of the
simvastatin occurred (Sugimoto,et al.2001). These findings indicated with the
co-administration of herbals, such as St. John's Wort, an alteration in the
therapeutics of drugs that are CYP3A4 substrates can occur.26
Until recently, a major difference between FMO and CYP was the
inability of exogenous xenobiotics to modulate FMO. There has been three in vivo
dose-response studies conducted in male Fischer 344 rats utilizing indole-3-
carbinol (1-3-C), as a modulator for FMO. The 1-3-C plant alkaloid produced from
the hydrolysis of indole glucosinolate (Katchamart,etal. 2000) is found in
cruciferous vegetables (Larsen-Su and Williams 1996, Katchamart,et al. 2000).
A reduction in FMO 1 activity and protein levels both in the liver and the intestine
and induction of CYP1A1 and CYP1A2 occurred. These studies demonstrated that
there was an inhibition and induction from one monooxygenase to another (Larsen-
Su and Williams 1996). Administration of 1-3-C has the potential to alter
metabolism of drugs that are substrates for both CYP and FMO, creating the
potential for drug interactions (Katchamart,et al.2000).
Lastly, it has been shown that bepatic Sprague Dawley rat FMO 1 was
induced by the administration of the polycyclic aromatic hydrocarbon 3-
methyicholanthrene (3MC). These results indicated an increase of transcriptional
FMO mRNA and enzymatic translational activity (Chung,et al.1997).
1.5.3. Substrate metabolite formation by both CYP and FMO
Discovery of substrates being metabolized by either CYP or FMO is
increasing. For example thioridazine, an antipsychotic, undergoes N-oxidization
by FMO and/or converted to 2-sulfoxide, which is metabolized by CYP toa
sulfone. The suiphone is the primary metabolite and has the greater antipsychotic27
effect in humans (Hodgson,et al.1995). The drug cimetidine, anH2receptor
antagonist, which is utilized for the therapeutic treatment of peptic ulcers and
gastric hypersecretory syndromes, undergoes metabolism to the S-oxide
metabolite. Both CYP and FMO are responsible for the formation ofan aliphatic
sulfoxide of cimetidine in which the biotransformation was greater in the human
jejunum than in both rabbit and rat (Lu,et al.1998).In vitromicrosomal
inhibition studies using rabbit jejunum revealed with coincubation of imipramine
(1 mM) the metabolite formation of cimetidine (0.4 mM) decreased by 45%.
These inhibition studies also demonstrated that in the rabbit jejunum FMO
contributed 70% to the sulfoxide metabolite formation of cimetidine and CYP in
combination with nonenzymatic oxidation contributed about 30% to cimetidine
sulfoxidation (Lu,et al.1998).
In a human liver microsomal study, clozapine (CLZ), an
antipsychotic drug, was metabolized by both FMO and CYP (Tugnait,et al.1997).
In humans, CLZ undergoes extensive hepatic metabolism of which CLZ N-oxide
and N-desmethyl-CLZ are the major metabolites. Various FMO isozymes from
several species were used in a study by Tugnait et a! (1997), which used purified
minipig FMO1, rabbit FMO2, and human FMO3. These purified FMO samples
were incubated with CLZ to evaluate FMO metabolism. Purified FMO3 formed
CLZ N-oxide,Km324 M and Vmaxof 76.9 mol/mg protein/mm. N-demethylation
was not observed in this study. FMO being heat labile, with further studies of
inhibition of FMO by heat inactivation verified FMO as the metabolicenzyme for,43
metabolite formation of the N-oxide, whereas CYP1A2 and CYP3A4 were found
to produce the N-desmethyl-CLZ metabolite (Tugnait,et al.1997). CLZ has been
reported to undergo N-oxidization by both FMO and CYP in human liver, however
in the rat liver and brain, FMO appears to be primarily responsible for catalyzing
the reaction (Fang 2000).
Other examples of crossover metabolism of CYP and FMO enzymes
are: (S)-nicotine and ranitidine. (S)-nicotine undergoes extensive metabolism in
humans and 90% of a dose can be accounted for in the urinary metabolites
(Cashman,et al.1996). Ranitidine, an H2-receptor antagonist, has ane.v.
bioavailability ranging from 50 to 60% and is excreted in the urine (Williams,et
al.1992). In rat and human liver microsomes, ranitidine was metabolized to its
major metabolite N-oxide by hepatic microsomal FMO. In human liver
microsomes, ranitidine was converted to its N- and S-oxides by FMO greater than
93% and to the desmethyl metabolite by CYP1A2, 2C19, and 2D6 as indicated in
the following table, Table 5. FMO3 produced a 4 to 1 ratio of N-versus S-oxide
form (Chung,et al.2000).Table 5: S-nicotine and ranitidine substrates are converted to metabolites by
individual CYP and FMO isozymes. Human liver microsomeswere utilized.
Substrate Metabolite Isozyme Reference
S-nicotine S-cotinine CYP2A6 (Cashman, et al.
S-nicotine N-i-oxideFMO3 1996)
RanitidineN- and S-oxide FMOi, (Chung, et al.
N-oxide FMO3 2000)
S-oxide FMO2
DesmethylranitidineFMO5
CYP2C 19,
1A2, 2D6
1.6. HUMAN TISSUE AND MODELS: SMALL INTESTINE
1.6.1. Intestinal structure
There are three major regions in the small intestine. They are: the
duodenum, which is the shortest at about 20 to 30 cm long and 3 to 5cm wide; the
jejunum, the middle section is approximately 2 meters long; and the ileum is the
distal end of the small intestine protruding into the colon, approximately 3 meters
long. In comparison, the wall of the jejunum is thicker and wider than in the
ileum. From the duodenum to the ileum there isa gradual narrowing of the lumen.
The small intestine is comprised of a mucosa, submucosa, muscularis, basolateral
membrane, crypt-villus axis, epithelial cells, goblet cells, paneth's cells, M cells,
caveolated cells and various junctional complexes such as tight junctions
(Thomson 1994).A major route for entry of exogenous compounds is the GI tract by
serving as an interface with the dietary environment and is the first potential site
for metabolism by the intestine (Renwick and George 1989). The GI tract consists
of muscular coats lined with mucosal cells that conduct drug oxidation regulating
the absorptive and secretory processes (Thomson 1994). The main functions of
the mucosa are: secretion of mucus; digestive enzymes and hormones; absorption
of the final products from digestion into the blood; and protection against
infectious disease (Marieb 2001).
Three sub-layers comprise the digestive mucosa which are: the
epithelial layer, a continuous sheet of epithelial cells lining the villi and the crypts;
the lamina propria; and the muscularis mucosa which provides structure for the
epithelial cells (Thomson 1994, Doherty and Charman 2002). When the sub-layers
are combined, the sub-layers are called the crypt-villus unit (Thomson 1994). The
epithelium lining contains the villi which contains absorptive cells (enterocytes)
for absorption of nutrients and drug molecules. The concentration of the villi and
microvilli is the highest in the duodenum and jejunum (Doherty and Charman
2002). Apical microvilli increase the apical surface area from 14 to 40 fold
(Madara and Trier 1994). The highest metabolic response is found in the pylorus
(opening from stomach to intestine) and small intestine, especially the duodenum
and jejunum (Caidwell and Marsh 1982, Renwick and George 1989). Figure 3
indicates individual sites in the intestinal mucosal layer.31
Figure 3: Schematic of small intestinal wall structure.
1.6.2. Intestinal function
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Drug metabolism in the GI tract occurs with oral and rectal
administration. With these types of administration, a xenobiotic can be
metabolized within the lumen or while in the process of being absorbed as it is
passing through the mucosa to make its way to the blood stream (Caldwell and
Marsh 1982). The pH is 7.5 in the small intestine, with a slight increase in the
cecum (junction of the ileum into the colon) to a pH of 8.0 (Renwick 1982).
Absorption of water and nutrients is the primary function of the small intestine.32
With activity, vasodilators such as vasoreactive intestinal peptidesare released
from the mucosa of the intestinal tract during digestion. Also, peptide hormones
such as cholecystokinin, gastrin, and secretin are secreted from the intestinal
mucosa. GI glands will also release kallidin and bradykinin into the gut wall,
which are vasodilators. Oxygen concentration also decreases in the gut wall during
GI activity resulting in vasodilation, probably due to the release of adenosine. All
of the aforementioned contribute to increased blood flow. The GI absorptive
capacity can be greatly diminished with a deficit of oxygen in the villus tips
creating ischemia, resulting in a blunted villi or the disintegration of the whole
villus (Guyton 1991, Madara and Trier 1994). Motor, secretory, and absorptive
activity all increase after a meal. Thus, blood flow can increase between 100 to
150 percent and last approximately 3 to 6 hours (Guyton 1991). Of the total
volume digested daily, 6 to 12 liters daily, only 10 to 20% passes into the colon
(Weisbrodt 1987, Guyton 1991).
A secondary function of the small intestine is the ability to
metabolize xenobiotics by phase I and phase II reactions by enzymes located in
the epithelial cells (Caidwell and Marsh 1982, Renwick and George 1989, Ilett, et
al. 1990, Krishna and Klotz 1994). There are two sources of enzymes in the
human intestinal lumen: mammalian and bacterial. The bacterial enzymes tend to
be more concentrated in the ileum and the colon than in the duodenum and
jejunum. The duodenum and the jejunum have the highest activity for phase I33
oxidation by CYP and phase IT conjugations, such as glucuronidation (Renwick
and George 1989).
There are two major pathways solutes will passively penetrate the
epithelial mucosa. They are the transcellular and the paracellular pathways. The
transcellular, which is across the cell into the cytosol, is accessible to lipophilic
compounds and essentially impermeant to passive flow of intermediate to large
hydrophilic compounds; therefore permeation by hydrophilic solutes penetrate
through tight junctions that join the epithelial cells. The tight junctions regulate
epithelial permeability through the paracellular flow of fluid (Madara and Trier
1994). Drug metabolizing enzymes are located in the enterocytes of the villi
therefore metabolic biotransformation can occur when the drug enters the cytosol.
Xenobiotics that are passively absorbed by way of the paracellular route are less
likely to undergo significant biotransformation (Doherty and Charman 2002).
With phase II conjugation reactions, saturation can occur with the
presence of excess substrate due to the low availability of cofactors. (Note:
saturation can also occur with phase I reactions). With saturation, dose-dependent
metabolism, and drug-drug interaction could occur with concomitant drug
administration. Sulfation and glucuronidation conjugation reactions are more
prevelant in the GI tract than phase I reactions (Caldwell and Marsh 1982).
However, unknown variables still exist such as the presence of FMO within the
intestinal mucosa, which could be a factor for determination.34
1.7. LIVER: MODEL FOR DETECTION OF HEPATIC INJURY
1.7.1. Introduction
The first part of this dissertation investigates the acute hepatotoxicity
of ketoconazole (KT) in SpragueDawley rats, thus a brief overview of the
function/hepatic injury will be briefly discussed. The liver as a major organ of
vertebrates conducts a complex role in excretion and detoxification. Xenobiotics
are metabolized in the intestine and liver and both organs can be responsible for
detoxication/bioactivation of orally administered drugs. The following diagram,
Figure 4, represents the relationship of the liver, gall bladder, and small intestine
within the human body, depicting the portal vein, hepatic artery, vena cava, and
common bile duct locations.Liver
gall bladder
portal vein
common bil
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Figure 4: Schematic of the human liver in relationship to small intestine. Adapted
from Klaassen (1996),
Within the liver, enzymes catalyzing xenobiotic biotransformation are
located primarily in the endoplasmic reticulum (ER) or the soluble fraction of the
cytoplasm, with lesser amounts in the mitochondria, nuclei, and lysosomes (Lewis
1998). A dual blood flow is supplied to the liver. Venous blood flows from the
gut, spleen, and pancreas (60 70 %) through the portal vein and on into the liver.
From the liver, the blood passes through millions of fine liver sinusoids, and
leaves the liver by the hepatic veins emptying into the vena cava (Guyton 1991).
Oxygenated blood enters the liver through the hepatic artery (3040% of blood
flow to the liver) and passes through the sinusoids (channels between cords of cells36
called hepatocytes) and is collected by hepatic veins that feed into thevena cava
(Klaassen 1996). This dual blood supply aids in maintaining metabolic
homeostasis. Cell types of the liver consist of: i) the parenchymal (hepatocytes)
that are involved in active plasma membrane turnover (endocytosis); ii) the
sinusoid cells, which are endothelial cells that exchange fluids and molecules such
as proteins (i.e. albumin); iii) the Kupffer cells, the macrophages located within the
lumen of the sinuosoids; and iv) the Ito cells, endothelial cells that store fat and
vitamin A (Klaassen 1996).
Figure 5 represents the acinus, the functional unit of the liver.
Terminal branches of the portal vein and hepatic artery extend out from the portal
tracts of the acinus. Blood supplied by the portal vein and hepatic artery flows
down the acinus past cords of hepatocytes. The acinus is divided into three
regions: zone 1, zone 2, and zone 3. Zone 1 is the closest to the blood entrance
and has the highest oxygen content, bile salt concentrations, and levels of
glutathione (GSH). Zone 3 contains the highest levels of CYP (Klaassen 1996).37
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Figure 5: Diagram of the acinus, the functional unit of the liver. Featured is the
blood and bile flow from the portal vein and hepatic artery passing throughzones
1, 2, and 3 (where metabolism occurs) and out through the terminal hepatic vein.
1.7.2. Liver function
The formation of bile fluid is a specialized function of the liver. The
bile, a dark yellow or brown-green alkaline secretion, contains cholesterol, bile
salts (emulsification of dietary fats), bile pigments (bilirubin and biliverdin),
lecithin, phospholipids, electrolytes, urea and various xenobiotics/metabolites
(Gilman, et al. 1996). The bile will be moved from the bile duct into the
duodenum by the pressure contractions of the gall bladder. The contents in the
bile may either be excreted or recycled to the parent xenobiotic anchor metabolites.
Recycling is referred to as enterohepatic circulation where a xenobioticcan
undergo reabsorption. If the enterohepatic circulation process occurs severaltimes, a longer half-life for a xenobiotic will occur (Gilman, et al. 1996, Klaassen
1996).
With age the liver decreases in weight (20% in males and 11% in
females) and appears brown due to an accumulation of pigmented waste products
within the hepatocytes, 'brown atrophy'. Blood flow in the aging liver is reduced
by 40%. Because phase I reactions are dependent upon oxygen, a reduction of
phase I metabolism can occur in the elderly. Thus, drug dosage regimens should
be altered for drugs that undergo phase I metabolism in aging patients (LeCouter
and McLean 1998).
1.8. INTESTINAL CELL LINES
1.8.1. Cell culture
Intestinal cell cultures were used in the second part of this
dissertation to detect the presence of FMO therefore a brief descriptive overview
of a cell line will be presented. Cell line culture is derived from intact or
dissociated tissues or an organ fragment known as a primary culture, as depicted in
Figure 6. When a primary culture is propagated to another culture vessel, it is
considered a subculture. The subculture is identified by a numbering system,
known as a passage. Sub-cultured populations are considered cell strains based
upon the expression of specific properties, functional characteristics, or markers.
If a subculture is derived from a single cell it is considered a clonal culture.39
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Figure 6: Schematic of a cell line lineage. Depicted are different types of cell lines
created from a primary culture.
1.8.2. Cell line background
Mixed function oxidase activities are present not only in the liver, but
also in other organs including the intestinal epithelium. Due to the anatomical
relationships and functional properties, the intestinal epithelium contains the
highest concentrations of ingested compounds resulting in an important role in
intestinal metabolism (Bonkovsky, et al. 1985). The epithelium is highly dynamic
and is continuously renewed by cell generation and migration from the
proliferative stem cell population. In non-cancerous epitheliall cell lines, such asintestinal CCL241 and colon CRL 1790, the size and shape properties of the cell
and nuclei are nearly uniform. Confluent cells will not pileup and the confluent
density is approximately 2 -16 xiO4cells/cm2. With malignant cells, the size and
shape of cells and nuclei vary with a confluent densityas high as 212 x 10
cells/cm2(Owens,et al.1976). Due to the unavailability and difficulty in
production of normal human intestinal epithelial cell lines, most of the information
concerning human intestinal cell regulation has been obtained from cell cultures
generated from experimental animals and the human colon cancerous lines, such
as Caco-2 cells (Perreault and Beaulieu 1998).
Even though Caco-2 cells are a colonic origin cell line, they
spontaneously differentiate into columnar cells when culturedin vitro.They
possess microvifli and have a polarized distribution of brush border enzymes,
resulting in barrier-like characteristics resembling human primary small intestinal
cells (Lampen,et al.1998). The Caco-2 cells have been used for i) transport of
drug studies (Karisson,et al.1993, Lampen,et al.1998), ii) transport of bile acid
investigation (Karlsson,et al.1993, Lampen,et al.1998), and, iii) expression of
glutathione-S-transferases (Peters and Roelofs 1992). Enzymes detected in Caco-2
cells are: CYP1A1, CYP2E1, and CYP3A (Lampen,et al.1998), but CYP3A4
has been found to be at low levels in Caco-2 cells. However, with continuous
culture and induction with Ia, 25-dihydroxyvitamin D, a large increase in
CYP3A4 activity occurs. A Caco-2 clone, TC7 cells, has been shown toexpress
after confluency higher levels of the expression of CYP3A4 in both mRNA and41
protein levels (Carriere,etat. 2001). CYP 1 Al, a bioactivator of procarcinogens
(McNicholas,etal. 1990, Cross,etal. 1991), in Caco-2 cells has been found to be
expressed at both the protein and mRNA levels. CYPIA1 also could be induced
byfl-naphtholflavone and 3-methylcholanthrene (3MC) (Lampen,etal. 1998).
Also, alkaline phosphatase activity has been detected in Caco-2 cells and is
considered a reliable marker for differentiated small intestinal enterocytes. Caco-2
cells have been a useful tool for evaluating metabolism of xenobiotics by the
intestine (Lampen,etat. 1998).
1.9. KETOCONAZOLE (KT)
1.9.1. Pharmacokinetics (ADME)
Part of this dissertation investigates the possible metabolic
bioactivation pathway associated with hepatotoxicity of KT, therefore a brief
overview of KT will be presented. KT, following an oral administration of a 200
mg dose with a meal has a mean peak plasma level of approximately 3.5 tg/mL,
which is reached within 1 to 2 hours. Metabolism of KT involves the conversion
into several metabolites, such as the oxidation and degradation of the imidazole
and piperazine rings, oxidative 0-dealkylation and aromatic hydroxylation.
Approximately 13% is excreted in the urine (24% unchanged), but the major
route of excretion is through the bile into the intestinal tract. KT appears dose-
dependent with a half-life from an oral 200 mg dose of 1.5 to 4 hours, but with
repeated dosing the half-life has been found to increase (Gascoigne,etat. 1981,42
Daneshmend,et al.1983, Daneshmend and Warnock 1988). With administration
of a higher dose (400 mg-KT/day), the half-life has been found to increase to 2.21
2.7 hours. In cancer patients, administration of a 400 to 800 mg-KT/day dose
results in a mean half-life of 3 hours has been observed ranging from 1.3 to 11.6
hours (Daneshmend and Warnock 1988). Itraconazole, an azole family member,
(Venkatakrishnan,et al.2000) also exhibited dose dependant kinetics after
multiple doses resulting in an increase in plasma levels. Absolute bioavailability
in conditions of saturated first-pass metabolism was higher (Heykants,et al.1989).
Both KT and itraconazole have been found to reversibly interact through an azole
nitrogen ligation with the heme group of CYP (Heykants,et al.1989,
Venkatakrishnan,et al.2000). Thus, long-term administration would result in auto
inhibition of metabolism and a potential problem for drug accumulation (Heel,et
al.1982). In human blood, only 1% of the compound KT is present as a free drug
in plasma (Daneshmend and Warnock 1988), 83.7% is bound to plasma proteins
and 15.3% is present within the blood cells (Daneshmend 1984). The therapeutic
concentrations, dosages, and duration of treatment for KT vary depending upon the
medical diagnosis. The mean peak serum concentrations of KT in humans range
from 8 pM to 19 pM after a 200 mg/day dose (Heel,et al.1982) and from 13 pM
to 26 pM following a 400 mg/day dose (Baxter,et al.1986). However, KT
plasma concentrations have been reported to be as high as 94 pM (Baxter,et al.
1986, Sugar,et al.1987). In humans, a disproportionate increase in the AUC has43
been observed following oral doses of 100, 200, 400, 600, and 800mg (Heel, et al.
1982). Figure 7 is a depiction of the molecular structure of KT.
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Figure 7: Structure of ketoconazole (KT). The compound is composed of
(depicted by arrow indicators) an acetyl group, a piperazine ring, oxyphenylgroup,
dioxolan ring, dichiorophenyl ring, a methyl group, and an imidazole ring.
1.9.2. Application and clinical usage
KT is a broad-spectrum antifungal, which is therapeutically effective
against systemic mycosis, especially in patients who are susceptible to
opportunistic systemic fungal infections. KT is administered orallyas a tablet or
capsule (200 to 400 mg), or topically as a shampoo,cream, or ointment (2%) (PDR1999).In fungi, KT blocks the conversion of lanosterol to ergosterol by inhibiting
the CYP, lanosterol 14 a-demethylase, for the oxidative removal of C-14 methyl
group from lanosterol. This incomplete removal results in a loss of membrane
integrity.
In rats, plasma levels of 24 pM and 62 pM of KT resulted from 10
mg/kg and 20 mg/kg doses, respectively (Gascoigne,et al.1981). After oral
administration in rats, KT and/or its metabolites have shown a higher
concentration in the liver than in the plasma (Gascoigne,etal. 1981, Whitehouse,
et al.1990). Specific tissue binding to hepatic microsomal fractions was reported
to be 89% (Daneshmend and Warnock 1988), indicating possible inhibition of
mixed function oxidative metabolism with the binding of KT to rat liverin vivo
andin vitro.
Accumulation of KT is of concern due to the inhibition of the
synthesis of testosterone when utilized for the therapeutic effects in the treatment
of androgen-dependent afflictions such as prostate cancer. Prostatecancer is the
second leading cause of cancer death in American men where the probability of
one in five men will develop prostate cancer during their lifetime (lIT 1999).
Inhibited are the precursors of testosterone. Inhibition of 17,20-lyase blocks the
synthesis of dehydroepiandrosterone and androstenedione (Bok and Small 1999).
High doses of KT 400 mg/8 hrs or 600-mg/12 hrs for six to nine months elicit
significant deprivation of androgen, the major contributor to elevating prostate
cancer (Decoster,et al.1996, Bok and Small 1999).45
1.9.3. Ketoconazole: adverse effects
There have been numerous documented cases of KT-induced
hepatotoxicity. The hepatotoxic symptoms can be mild to severe and may develop
within two days or up to one year after the initiation of therapy (Knight,et al.
1991). It has been speculated that the hepatotoxicity associated with KT may be a
result of the parent compound andlor reactive metabolite(s) that covalently binds
with hepatic macromolecules, thereby producing hepatic damage (Buckholz and
Rodriguez 2000). The hepatotoxicity appears to be reversible with discontinued
use of KT (Lewis,et al.1984, Chien,et al.1997). KT administration has been
associated with fatalities (Duarte,et al.1984, Janssen 1995) and numerous cases
of hepatitis, resulting in an increase in serum liver enzymes from liver cytosolic
enzymes indicating possible hepatic damage (MacNair,et al.1981, Lewis,et al.
1984, Stricker,et al.1986, Knight,et al.1991, Chien,et al.1997). Other
symptomatic problems include malaise, dark urine, jaundice (Van Parys,et al.
1987), headache, dizziness, drowsiness, and papilloedema (Bok and Small 1999).
The first reported KT-induced hepatitis was in 1981 (MacNair,et al.
1981), and the first fatality occurred in 1982 due to hepatic coma (Duarte,et al.
1984). Sudden hepatitis has led to several deaths even though the patients undergo
frequent laboratory and clinical evaluations (Lewis,et al.1984, Duarte,et al.
1984, Bercoff,et al.1985, Stricker,et al.1986). Two other patients that suffered
KT-induced hepatitis survived due to liver transplants (Knight,etal.1991, Brusko
and Marten 1991). The autopsy of a patient who died of KT treatment revealedmassive hepatocellular necrosis (Lewis,et al.1984). Moreover, a European trial
of high dose KT (1,200 mg/day) for prostate cancer resulted in 11 deaths out of
350 participants within two weeks of starting the high-dose therapy (Janssen
1995).
Mechanistic evaluation could aid in future structural analysis of an
entire chemical family, such as the azoles. Clinical symptoms, suchas increases in
serum bilirubin and alanine transaminase (Van Parys,et al.1987) indicate cellular
damage, but the toxic mechanistic profile of KT is still unclear in humans (Bok
and Small 1999) and animals. It is suspected that toxicityresponses are not due to
an immunoallergic mechanism (Bok and Small 1999), but a direct attack by either
KT and/or its metabolites (Lewis,et al.1984, Stricker,et al.1986, Brusko and
Marten 1991). Clinical results involving 270 patients demonstrated KT
administration and the injury that was incurred was metabolic rather thana
hypersensitive idiosyncracy (Chien,et al.1997). Anin vitrostudy using cultured
rat hepatocytes demonstrated that the primary metabolite of KT, N-deacetyl
ketoconazole (DAK), was more hepatotoxic than KT (Rodriguez and Acosta
1997). It has been established that the primary metabolite, DAK, undergoes FMO-
mediated metabolism to the N-deacetyl-N-hydroxy ketoconazole (N-hydroxy-
DAK) metabolite depicted in Figure 8 (Rodriguez and Acosta 1997, Rodriguez,et
al. 1999). The N-hydroxy-DAK metabolite is a secondary hydroxylamine,47
which is susceptible to further FMO-mediated oxidative reactions. Further FMO
oxidation could produce toxic and reactive metabolites that might be responsible,
in part, for the toxicity of KT./__\/=\
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Figure 8: N-deacetyl ketoconazole (DAK) and N-hydroxy-N-deacetyl
ketoconazole (N-hydroxy-DAK).To date, there has not been a mechanistic determination of the
hepatotoxicity associated with KT in vivo as well as the investigation of the FMO
isoforms within the human intestine and representative intestinal cell lines. The
first part of this dissertation will evaluate the possible metabolic bioactivation
pathways of KT by CYP or FMO, which could be responsible for producing toxic
metabolites resulting in hepatic injury. The second part of this dissertation
investigates the presence of individual FMO isoforms within the human intestinal
tract components, as well as intestinal, human epithelial colon, and the colorectal
Caco-2 cell line. Detection of FMO could aid in future predictions of drug
metabolism and the outcome of an administered drug metabolized by FMO. The
presence of FMO could result in reduced bioavailability due to a first-pass effect
and/or toxicity effect with increased serum concentrations from modulation of
FMO.50
CHAPTER 2:HEPATOXICITY OF KETOCONAZOLE IN SPRAGUE
DAWLEY RATS: GLUTATHIONE DEPLETION, FLA YIN-CONTAINING
MONOOXYGENASES-MEDIATED BIOACTIVATION, AND HEPATIC
COVALENT BINDING
C. J. Buckholz and R. J. Rodriguez
Submitted to Xenobiotica51
2.1. ABSTRACT
This study evaluates ketoconazole (KT)-induced hepatotoxicity using
in vivoandinvitro approaches.In vivoexperiments were conducted using male
Sprague-Dawley (SD) rats with 3H-KT (1.5 tCi/mg) at 40 and 90mg KTIkg doses.
Blood and liver samples were collected 0 thru 24 hours for alanine
aminotransaminase (ALT), glutathione (GSH), and covalent binding analyses.
Covalent binding occurred as early as 0.5 hour, peaked at 2 hours (0.026 ± 0.01 nmol
KT/mg protein) and 8 hours (0.088 ± 0.04 nmol KT/mg protein) for 40 and 90 mg
KTIkg doses, respectively. Increases in ALT levels occurred at 0.5-hour for the 40
and 90 mg KTIkg doses (44.3 and 56.4 U/mL, respectively) in comparison to control,
22.7 U/mL. The 90 mg KTIkg dose at 24 hours reduced hepatic GSH levels from
9.92 ± 1.1 to 4.76 ± 0.3 nmol GSH/mg hepatic protein. Experiments to evaluate the
role of the flavin-containing monooxygenases (FMO) utilized SD hepatic
microsomes with 1, 10, and 100 tM [3H] KT. Maximum covalent binding occurred
at 100 tM KT. Heat inactivation of microsomal-FMO significantly decreased
covalent binding by 75% while 1 mM GSH significantly reduced covalent binding
by 65%. Co-treatment (heat inactivation and 1 mM GSH) resulted in 80% decreased
covalent binding. Thus, KT-induced hepatotoxicity is dose- and time-dependent and
appears to be FMO-mediated, in part, to metabolites that may react with protein and
possibly, GSH.52
2.2. INTRODUCTION
Analysis in vivo was conducted with Sprague Dawley (SD) rats to
determine if a dose- and time-dependent response would result in tight or covalent
binding effects, as well as to establish a correlation witha change in serum
enzymes indicated by the release and reduction of alanine transaminase (ALT) and
glutathione (GSH), respectively. Elucidation of these effects would indicatea
relationship between metabolism, toxicity, and covalent binding. A reduction of
GSH would be expected if bio activation of an electrophilic metabolite occurred
due to the conjugating nature of this cellular scavenger to preserve the integrity of
the cell (Hogberg and Kristoferson 1977b). Comparative analysis in vitro with SD
microsomes were conducted to determine if covalent binding effects would occur
in vitro also and due to the nature of GSH as an electophilic scavenger by
detoxification through conjugation (Hogberg and Kristoferson 1977a), covalent
binding analysis was implement with the addition of 1 mM GSH (Cribb, et al.
199 1, Pirmohamed, et al. 1995) to determine if the addition of GSH would alter
binding effects in microsomal preparations. To determine the involvement of CYP
and/or FMO bioactivation a comparative evaluation of covalent binding of KT,
heat inactivation was implemented in vitro due to the heat lability of the FMO
enzyme (Ziegler 1980). Also due to reported inhibition and induction of FMO and
CYP by 1-3-C in the liver and intestine of Fischer 344 rats (Larsen-Su and
Williams 1996, Cashman, Xiong, Lin, et al. 1999, Katchamart, et al. 2000),
respectively, in vitro analysis utilizing Fischer 344 rat microsomes (treated with I-53
3-C)for covalent binding effects was implemented. The hepatotoxicity of KT is
possibly due to a covalent binding effect with hepatic macromolecules by the
parent compound and/or reactive metabolites; thereby producing hepatic damage.
These experimental findings will aid in establishinga correlation between thein
vivo andin vitrostudies.54
2.3. MATERIALS AND METHODS
2.3.1. Chemicals and Supplies
KT was a generous gift from Janssen Pharmaceuticals (Olen,
Belgium), 3H- KT (5 Ci/mmole, 98% purity) was purchased from American
Radiolabeled Chemicals, Inc., (St. Louis, MO). Reduced glutathione (GSH),
oxidized glutathione (GSSH) reductase, 5,5'-dithiobis(2-nitrobenzoic acid)
(DTNB), NAPDH, trichloroacetic acid (TCA), sodium hydroxide, Trizma,
ethylenediaminetetraacetic acid (EDTA), sucrose, glycerol, glucose-6-phosphate,
glucose-6-phosphate dehydrogenase, and NADP+ were purchased from Sigma (St.
Louis, MO). Alanine aminotransaminase (ALT) analysiswas conducted with
Sigma Diagnostics Transaminases kit (ALT/GPT), No. 505-P, (St. Louis, MO).
HPLC grade methanol was purchased from Fisher Scientific (Fair Lawn, NJ) and
CytoScint was purchased from ICN (Costa Mesa, CA). Sprague-Dawley (SD) rats
were purchased from Simonsen Laboratories, Inc. (Gilroy, CA).
2.3.2. Statistical analysis-invivo andin vitroSD rat covalent binding,
GSH, ALT analyses, and SD microsomes:
SD rat statistical analysis of the analysis of variance (ANOVA) was
performed by SAS statistical program, version 8.01, from SAS Institute, Inc.,
(Cary, NC) to determinein vivocovalent binding significance. Tukey's multiple
comparison was performed for thein vivoALT study and Dunnett's multiple
comparison was performed for thein vivoGSH studies. ANOVA analyses were
performed for thein vitrodose- and time-response studies of SD hepatic55
microsomes, GSH, and heat inactivation analysis. Probability values of P0.05
were considered statistically significant.
2.3.3. Methods
2.3.3.1. Animal treatment and collection
Male SD rats (200220 g) were treated intraperitoneafly (ip) with
3H-KT (1.5 tCi1mg) at doses of 40 and 90mg KT/kg. Control rats were treated
with 0.9% normal saline. Blood and liver samples were collected at 0, 0.5, 1, 2, 4,
8, 12 and 24 hours for ALT, GSH, and covalent binding analyses. The blood
samples and approximately 1.1 gm of the liver were placed on ice for ALT, GSH,
covalent binding, and protein determination. The remaining liver samples were
snap-frozen and placed in a 80
°C freezer for metabolite isolation, purification,
and identification studies. All experiments were performed in triplicate.
2.3.3.2. In vivo-SD rat covalent bjndin, alanine aminotransaminase
(ALT), and glutathione (GSH) analysis: (Protocols A, B, and C)
After the male SD rats were administered 3H-KT (1.5 tCi/mg) at
doses of 40 and 90 mg KTfkg, approximately I gram from each of the liver
samples were homogenized with homogenization buffer. One mL of the
homogenate was mixed with ice-cold trichioroacetic acid (TCA) and centrifuged
for 10 minutes to precipitate the protein. The pellet was then washed thrice with
ice-cold TCA and then washed six times with ice-cold methanol, until the56
supernatant fraction of the wash achieved background levels of radioactivity. The
final protein pellet was dissolved at 60 C for 1 hour and aliquoted into
scintillation vials containing scintillation fluid with 1.5% (vlv) glacial acetic acid.
Radioactivity was measured in disintegrations per minute (dpms) and normalized
to nmol KT/mg protein. Protein concentrations were determined using the
CoomassieP1u5TMProtein Assay from Pierce (Rockford, IL). All studies were
performed in triplicate.
ALT serum determinations were conducted utilizing blood samples
collected at 0, 0.5, 1, 2, 4, 8, 12, and 24-hour time points and the blood samples
were immediately placed on ice and allowed to coagulate prior to centrifugation at
4 C and 8,000 x g (Protocol B). The serum was collected and kepton ice. The
ALT was assayed using a modified procedure for small sample volumes. Alanine
alpha-ketoglutarate was placed into a test tube into a 37 C water bath with the
addition of serum and normal saline. The sample mixturewas gently mixed and
placed back into the 37 ° C water bath and incubated. After incubation, the color
reagent was added to the incubation-mixture, vortexed (low speed), and left at
room temperature for 20 minutes, then 0.4 N NaOH was added to the mixture and
vortexed. After 5 mm, an allotted amount of the sample mixture was placed intoa
96-well plate and the absorbance was measured spectrophotometrically in
units/nTh (U/mL). ALT catalyzes conversion of alpha-ketoglutarate and alanine to
glutamate and pyruvate. Comparisons were made with control rats injected with
normal saline. All experiments were performed in triplicate.57
Collection of liver samples occurred between 8:30 AM and 11:30
AM to avoid diurnal pattern variations (Jaeger et al. 1973). The method of
Roberts and Francetic in 1993 was used for GSH analysis. A 50 mg liver sample
was immediately removed from the rat, blotted dry, weighed, and placed in
sulfosalicylic acid (SSA, w/v in water) (Protocol C). The liver samples were
homogenized and centrifuged for 10 minutes. The resulting supernatant was
diluted 10-fold with sample buffer and placed on ice. A 300 uL aliquot of the
sample was combined in a vial with sample buffer, and vortexed. A100 1uL sample
was placed into a 96-well plate in duplicate. After a 1 minute incubation in the 96-
well plate, 100 uL NADPH was added to the sample mixture, mixed, and
absorbance was monitored on a spectrophotometer at 412 nm at time zero and
every 30 seconds for 1.5 minutes. The change in absorbance per minute was
determined and converted to ,umol GSH using a calibration curve with known
standards. The results were expressed inmo1 GSWg protein.
2.3.3.3. SD rat in vitro microsomal preparation for covalent binding
analysis: (Protocol D)
The liver tissues were removed from male SD rats and immediately
placed on ice. The tissues were homogenized in homogenization buffer.
Microsomes were prepared by standard differential centrifugation and stored in
resuspension buffer, pH 7.5. The microsomes were frozen in liquid nitrogen and
stored at 80 C. Protein concentrations were determined using the CoomassieP1usTM Protein Assay from Pierce (Rockford, IL). Fischerrat microsomes were
courtesy of Dr. D. E. Williams, Oregon State University, Corvallis, Oregon.
2.3.3.4. SD rat in vitro covalent binding, GSH, and metabolic pathway
analyses in hepatic microsomes:(Protocol E)
Covalent binding of KT and/or its metabolites to hepatic microsomal
protein and a protein variation analyses were performed to determine linearity. The
microsomal-incubation mixture consisted of three different microsomal protein
concentrations, incubation buffer, increasing concentrations of KT with 3H-KT (1
iCi/mL), and the NADPH-generating system and was incubated at 37 ° C in a total
volume of 0.5 mL. A negative control without the NADPH-generating systemwas
performed with each experiment. The microsomal-incubations were terminated at
respective time points and the protein was precipitated, washed, and radioactivity
was determined. All experiments were performed in triplicate.
To evaluate the affect of GSH on the 'covalent' binding of KT and/or
its metabolites, co-incubations of 100 tM 3H-KT (1 tCi/mL) and 1 mM GSH
using the 1 mg/mL microsomal-incubations in were performed in triplicate and
terminated at the 0, 1, 4, and S hour time points.
To evaluate the effect of FMO on the covalent binding of KT and/or
its metabolites, microsomal-FMO activity, not CYP activity,was inhibited by
heat-inactivation (Ziegler 1980). The microsomes were heated at 50 ° C for 90 sec
before adding them to the incubation mixture containing 100 tM 3H-KT (1
.tCi/mL), I mg/mi. microsomal protein, and incubation buffer fora total volume of59
0.5 niL. The microsomal incubation was terminated at 0, 1, 4, and 8 hours with
0.5 mL 0.9 M trichloroacetic acid (TCA). Lastly, heat-inactivation and 1 mM
GSH incubation was performed with 100 tM 3H-KT (1 tCiImL), 1 mglmL
microsomal protein, and incubation buffer for a total of 0.5 mLwas performed at
0, 1, 4, and 8 hours (Protocol B). Comparisons of GSH incubations and heat-
inactivated experiments were compared with the normal experimental conditions.
2.3.3.5. In vitro microsomal analyses of pretreated Fischer rats with
indole-3-carbinol (1-3-C)
Due to a predicted inhibition of the FMO enzyme by 1-3-C in the
liver and intestine of Fischer 344 rats (Larsen-Su and Williams 1996, Cashman,
Xiong, Lin,etal. 1999) and reported induction of CYP (Katchamart,etal. 2000),
comparative experiments were conducted to observe whether covalent binding
would occur where possible inhibition of FMO would occur. Three experiments
utilizing microsomes from pretreated Fischer 344 rats with 1-3-Cwere conducted
with a concentration of 1 mM microsomal protein, 10 tM of KT with 3H-KT (1
tCi/niL), and the NADPH-generating system, incubated at 37 ° C ina totalvolume of 0.5 mL (Protocol E) and terminated at the 0, 0.5, 1, 2, and 4-hour time
points. The protein was precipitated, washed, and radioactivitywas determined.
The negative controls were the microsomes from rats untreated with 1-3-C. The
protein concentration for each sample was as follows in mg/mL: Control, 1A
47.27, lB = 46.66; 2500 ppm, lA= 45.05, 1 B = 43.29; and dimer 2500 ppm, 1 A
= 48.87, 1 B = 48.46. All experiments were performed in triplicate.61
2.4. RESULTS- COVALENT BINDING ANALYSES
2.4.1. In vivo SD rat covalent binding analyses
Figure 9 shows the covalent binding of KT-derived [3HJ to hepatic
proteins from SD rats treated i.p. with KT (40 mg/kg or 90 mg/kg; 1.5 tCi/mg).
The radioactivity was normalized to nmol KT/mg hepatic protein. The 40 mg/kg
dose represents a low dose that will be expected to produce KT plasma
concentrations in the 1060 tM range while the 90 mg/kg represents high-dose
treatment for prostate cancer that will produce KT concentrations in the 75100
tM range. There was a significant difference between KT-derived {3H1-binding to
hepatic protein over the 24-hour period using ANOVA (P = 0.014, n3).
Covalent binding occurred as early as 0.5 hour after treatment for both doses. The
40 mg KTtkg dose peaked at 2 hours (0.03 ± 0.01 nmol KT/mg protein) with a
steady decline. The 90 mg KT/kg dose peaked at 8 hours (0.09 ± 0.04 nmol
KT/mg protein), and then there was a steady decline to the 24-hour time point
(0.04 ± 0.02 nmol KT/mg protein). All results are reported as the mean ± the
standard deviation.AU.
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Figure 9: 'Covalent' binding of ketoconazole (KT) to hepatic proteins in Sprague Dawleyrats. Treatment
was ip with 3H-KT (40 mg/kg or 90 mg/kg; 1.5 jiCi/mg). The radioactivity was normalized to nmol
ketoconazole-derived [3H]/mg hepatic protein. Therewas a significant difference between the 40 and 90 mg/kg
treatments over time using ANOVA (P = 0.014, n = 3).63
Figure 10 shows the effect of ip administration of KT, 40 mg/kg or
90 mg/kg, on serum ALT activity in SD rats. Due to diurnal variation concerns
regarding GSH levels, all doses were initiated to coordinate extractions between 7
and 11 am when GSH levels would be at the highest level. Interestingly, there was
an immediate increase in ALT levels as early as 0.5 hours after treatment for both
doses (44.2 U/mi. and 56.4 U/mL for the 40 mg/kg and 90 mg/kg doses,
respectively). The control rats treated with normal saline had an ALT value of
22.7 ± 9.7 U/niL.
There was an apparent and steady increase in ALT levels from 8
hours to 24 hours for the 90 mg KT/kg dose and a significant difference between
90 mg KT/kg dose and control using Tukey's multiple comparison (P < 0.05).
Also, there was a significant difference between the 40 mg/kg and 90 mg/kg doses
at the 12-hour and 24-hour time points after KT administration using Tukey's
multiple comparison (P <0.05).4OmgKT/kg
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Figure 10: Graph of serum alanine aminotransarninase (ALT) activity after administrationof ketoconazole
(KT) in Sprague Dawley (SD) rats. Treatment concentrationwas 40 mg/kg or 90 mg/kg. The dashed line
represents the ALT control value of saline-treated rats, 22.7 ± 9.7 U/mL. Tukey's multiple comparison
indicates significant differences between 90 mg KT/kg dose and control and between40 mg KT/kg and 90
mg KT/kg doses (P < 0.05).65
Figure 11 demonstrated the effect of KT on hepatic GSH levels in SD
rats. Due to diurnal variation concerns regarding GSH levels, all doses were
conducted to coordinate extractions between 8:30 and 11:30 am, when GSH levels
would be at the highest level. The hepatic GSH levels implicated for the control
rats were 9.66 ± 1.51 nmol GSH/mg protein. There was a significant difference
between the 40 mg KT/mg and the control rats at 0.5 hours and 8 hours where the
GSH levels were 6.89 ± 1.1 nmol GSHImg protein and 5.87 ± 1.1 nmol GSHJmg
protein, respectively (P < 0.05). Afterwards, the GSH levels increased back to
control values. The 90 mg KT/kg was significantly different from the control rats
at 4, 8, 12, and 24 hours where the GSH levels were 6.1 ± 0.91, 4.7 ± 0.19, 4.17 ±
0.9, and 4.76 ± 0.34 nmol GSH/mg protein, respectively using the Dunnett's
multiple comparison (P <0.05). At 24 hours, there was a significant difference
between the 40 mg/kg and 90 mg/kg doses, 8.55 ± 1.64 nmol GSH/mg protein and
4.76 ± 0.34 nmol GSHJmg protein, respectively (P <0.05).U-4OmgKTIkg
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Figure 11: Graph of hepatic glutathione (GSH) levels after ip administrationof ketoconazole (KT) in Sprague
Dawley rats. Treatment concentration was 40 mg/kgor 90 mg/kg. The dashed line represents the GSH
control value of saline-treated rats, 9.66 ± 1.51 nmol GSH/mg protein. Dunnett'smultiple comparison
indicated a significant difference between 40mg KT/mg dose or 90 mg KT/kg dose and control (P < 0.05).2.4.2. SD rat in vitro covalent binding with hepatic microsomes
The covalent binding of 3H-KT (1M, 10 tM, and 100 pM; 1 pCi/mL)
to hepatic microsomes from SD rats in an in vitro NADPH-generating system
containing 1 mg/mL hepatic microsomal protein is shown in Figure 12. Controls
without NADPH were used for comparison for each concentration studied. The
radioactivity was normalized to nmol KT/mg microsomal protein. All three KT
incubation concentrations, 1 tM, 10 jIM, and 100 riM, resulted in significant
differences with control incubation conditions using an ANOVA (P 0.01). As
the concentration of KT increased, so did the covalent binding to hepatic protein.
In addition, there appeared to be an increase in covalent binding with increasing
incubation periods for the 10 tM and 100 tM KT. The 100 tM KT incubation had
the highest covalent binding at 8 hours (0.51±0.06 nmol KT/mg of protein). The
control levels at 8 hours were approximately 10-fold lower (0.06±0.01 nmol
KT/mg of protein); thus, indicating an NADPH dependent mechanism of covalent
binding of KT-derived activity. The profile for the 1 tM KT-incubation ata
protein concentration of 1 mg/mL was consistent throughout ranging from 0.0027
±0.004 nmol KTI mg of protein to the highest at the 2-hour time point of 0.018±
0.00002 nmol KT/ mg of protein. The 10 tM KT-incubationappears to reach a
plateau at 2 hours, with the highest point of binding at 0.157±0.02 nmol KT/ mg
of protein. Thus, there is a dose proportionality between I and 10 tM KT and
saturation at 100 tM KT which is NADPH-dependent. The protein concentration
experiments of 0.250, 0.50, and 1 mg/mI produced the same metabolic profilewhen comparing the 3H-KT 1, 10, and 100 tM doses within each experiment.
There was a linear increase over time (0 through 8 hours) in the covalent binding
of KT to the hepatic protein with 0.25 mg/mL microsomal proteins having a
plateau at 3 hours (data not shown).-
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Figure 12: The covalent binding analysis conducted in vitro from the addition of
3H-ketoconazole (KT) in hepatic microsomes from Sprague-Dawley (SD)rats. 3H-
KT (1 tCi/mL) was in an NADPH-generating system. Controls without NADPH
were used for comparison for each concentration. The radioactivity was
normalized to nmol KT/mg microsomal protein. In Figure 14a, (*) indicatesa
significant difference between the 1 tM KT and control using ANOVA (P<0.05,
n=6). In Figure 14b, (*) indicates a significant difference between the 10 tM KT
and control using ANOVA (P O.05, n=6). Figure 14c, (*) indicates a significant
difference between 100 tM KT and control using ANOVA (P 0.05,n=6).70
The in vitro covalent binding of 100 tM 3H-KT (1 PCi/niL) to
hepatic microsomes (1 mglmL) from SD rats inan NADPH-generating system
with 1 mM GSH is shown in Figure 13. Control incubations without GSHwere
used for comparison for each of the time points evaluated. The radioactivitywas
normalized to nmol KT/mg microsomal protein. Therewas a significant reduction
of covalent binding to hepatic protein at the 4-hour and 8-hour using ANOVA(P
0.01); even as early as 1 hour after treatment, metabolic activationappears to
occur; thus suggesting that KT might also bind to hepatic GSH.-
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Figure 13: In vitro graph indicates reduction of 311-ketoconazole (KT-100 tiM)covalent binding effect to SD rat hepatic
microsomes after the addition of 10OiM glutathione (GSH). Treatment of microsomesconsisted of 3H-KT
(1 jiCi/mL) and ketoconazole (1, 10, and 100 iM)inan NADPH-generating system. Controls without GSH were
used for comparison. The radioactivitywas normalized to nmol KT/mg microsomal protein. The (*) indicated a
significant difference using ANOVA (P0.05, n = 6).72
Figure 14 shows the effect of heat inactivation (HI) on in vitro
covalent binding of 1OOtM 3H-KT (1 tCi/mL) to SD rat hepatic microsomes inan
NADPH-generating system containing I mglmL microsomal protein.Control
incubations without HI treatment were used for comparison at each time point
evaluated. The radioactivity was normalized to nmol KT/mg microsomal protein.
Interestingly, HI significantly reduced the covalent binding of KT-derived
radioactivity to the hepatic protein at the 1, 4, and 8-hour time points using
ANOVA (P < 0.05). The 8-hour incubation hada greater than 4-fold decrease
from 0.46 ± 0.06 nmol KT/mg protein to 0.11 ± 0.01 nmol KT/mg protein.-
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Figure 14: In vitro graph indicates reduction of 3H-ketoconazole (KT) 'covalent'binding effect from heat
inactivation (HI), 50 °C for 90 sec in Sprague Dawley (SD) rat hepatic microsomes.Treatment of
microsomes consisted of 3H-KT (1 tCi/mL) and ketoconazole (100 jiM) inan NADPH-generating system.
Controls without HI were used for comparison. The radioactivitywas normalized to nmol KT/mg
microsomal protein. An asterisk (*) indicatesa significant difference using ANOVA (P0.05, n = 6).74
The largest reduction of covalent binding occurred when bothwere
applied with a final result at the 8-hour time point of 0.0900± 0.0075 nmol KT/mg
protein. Figure 15 a and b depicts a comparison of GSH-KT, HI-KT with KT only
and Figure 16 is a comparative analysis of the GSH-KT and HI-KT withco-
incubation of GSH-HI-KT.a)
b)
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Figure 15: Graphs a and b depict thein vitrocomparisons of 3H-ketoconazole
(KT) (1 uCi/mL) covalent binding effect in Sprague Dawley (SD) rat hepatic
microsomal incubations (1 mg/mL) with/without the addition of glutathione (GSH,
1mM) and heat inactivation (HI). a: SD hepatic microsomal (1 mg/mL)
incubationin vitrocomparison of 1 mM GSH,KT (100 tM), 3H-KT (1tCi/mL)
with GSH (1 mM)-HI-KT (100 tM). b: SD hepatic microsomal (1 mg/mL)
incubationin vitrocomparison of HI and KT (100 tM) with GSH (1 mM)-HI-KT
(100 tM).76
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Figure 16: A comparative analysis of in vitro studies. Implementedwere the
combined procedures of GSH (1 mM)-heat inactivation (HI)- KT (100 tM).
Comparison with individual experimental analysis of GSH (1 mM), heat
inactivation (HI), and KT (100 tM) covalent binding studies resulted in the lowest
covalent binding of (KT)/metabolite(s) in Sprague Dawley rat microsomes (1
mg/mL). The radioactivity was normalized to nmol of KT/mg of protein.77
2.4.3. Fischer 344 rat in vitro covalent binding in hepatic microsomes
with and without 1-3-C
Figure 17a is a comparison of microsomal preparations of Fischer
344 rats with and without 1-3-C. Three experimentswere conducted using
microsomes from Fischer rats pretreated with 1-3-C utilizinga KT concentration of
10 tM at 0, 0.5, 1, 2, and 4-hour time points. Controls were Fischer rat
microsomes without 1-3-C pretreatment. Results indicated covalent binding
effects at all time points when compared with the controls withan early peak at 0.5
hour of 0.086 ± 0.002 nmol of KT/mg of protein for the 2500 PPM anda later
peak at 2 hours of 0.07 ± 0.002 nmol of KT/mg of protein for the dimer. The
highest indication of binding for the controlswas at two hours with a peak of
0.027 ± 0.01 nmol of ketoconazole/mg of protein. Figure 17b isa comparison of
covalent binding in SD microsomal preparations (Figure 12) with Fischer 344
hepatic microsomes utilizing 10 tM for comparative results. The 2500ppm
indicated a decline by the 2-hour time point (0.068 ± 0.006), and the dimer
increased to the 2-hour time point (0.07 1 ± 0.001) and declined to 0.06 ± 0.002 at
the 4-hour time-point, whereas the SD microsomal preparations utilizing 10 uM
peaked higher at 0.111 ± 0.011 at 2 hours with a slight decline at the 4-hour (0.09
± 0.02 1) time point.a)
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Figure 17: Graphs a and b depict an in vitro comparison of 10 tM of ketoconazole
(KT) in microsomal incubations (1 mg/mL) from Fischer rats with and without
(control) 1-3-C pretreatment and SD rat microsomes. Concentration of
radioactivity of 3H-ketoconazole (KT) was 1 tCi/mL. a) Samples with 1-3-C are:
2500 PPM and 2500 PPM-dimer. b) Comparative hepatic microsomal analysis of
Fischer and SD rats.79
2.5. DISCUSSION
This study is the first to investigate the hepatotoxicity associated
with KTin vivo.All of theinvivo parameters evaluated, ALT levels, hepatic GSH
levels, and hepatic covalent binding, suggest that KT produce hepatic injuryas
indicated with increases in ALT levels after KT administration (Figure 10). This
hepatic injury occurred as early as 0.5 hr with both the 40 mg/kg and 90 mg/kg
doses. The 90 mg KT/kg dose is representative of high dose KT treatment that is
seen in patients treated for prostate cancer. The high-dose KT therapy for prostate
cancer ranges from 400 mg KT/8 hours or 600 mg KT/12 hours for a total daily
dose of 1,200 mg for six to nine months (Decoster, et al. 1996, Bok and Small
1999). Shown in Figure 10, there is an initial and significant increase in ALT
levels for the 40 and 90 mg KT/kg dose. The 90mg KT/kg declines after 4 hours
and then increases at 12 hours and 24 hours. In the past hepatic injurywas suspect
as being a reaction assault by KT or its metabolite(s) and not due to an
immunoallergic response (Lewis,etal. 1984, Stricker,etal. 1986, Bok and Small
1999). Thus, the early release of ALT may be due to the parent compound, KT,
while the later increase of ALT at 12 and 24 hours may be due to reactive
metabolite(s).
The present study also investigated the possibility that KT may covalently
bind to hepatic macromolecules and/or hepatic GSH ina dose- and time-dependent
response. Figure 9 demonstratedin vivothat there was a definite dose-response in KT
covalent binding to hepatic SD rat protein. The 90mg KT/kg dose produced higherø1IJ
levels of nmol of KT-Derived [3H]/mg of protein in comparison to the 40mg KT/kg
dose over the 24-hour time period. Figure 11 indicated hepatic GSH levelswere
significantly decreased after a 90 mg KT/kg dose ina dose-dependent manner. The 90
mg KT/kg dose resulted in lower hepatic GSH levels than the 40 mg KT/kg dose at 4,
8, 12, and 24-hour time points with the greatest difference between the doses at 24
hours. In the 40 mg KT/kg dose, the GSH levels appear to decrease from 0 thru 8
hours, then increase back to control GSH levels at 12 and 24 hours. It is likely the
liver was able to recover from low dose treatment and return to normal hepatic GSH
levels. On the other hand, the 90mg KT/kg treatment continued to deplete the hepatic
GSH at the 12-hour and 24-hour time points. When comparing thein vivohepatic
GSH levels to the 'covalent' binding studies of KT to hepatic protein and the ALT
studies, no significant correlationswere made between thein vivoalterations in ALT
and GSH levels (Figures 10 and 11, respectively) to the covalent binding (Figure 9)
that occurred.
It is possible that as KT undergoes oxidative metabolism such that the
metabolite(s) of KT may be reacting to GSH because the decrease in GSHoccurs
hours after exposure to KT rather than earlier. Thus, the parent compound, KT,
may be directly binding to hepatic protein while the metabolite(s) are binding to
hepatic protein and hepatic GSH. Earlier studies indicate the primary metabolite of
KT is N-deacetyl ketoconazole (DAK) in mice (Whitehouse,et al.1990) and rat
(Rodriguez and Acosta 1997, Rodriguez,et al.1999) and DAK was more
hepatotoxic in anin vitrorat hepatocyte culture system (Rodriguez and Acosta1997). Furthermore, DAK is further metabolized by FMO to the N-deacetyl-N-
hydroxy ketoconazole, a secondary hydroxylamine (N-hydroxy-DAK), metabolite
(Rodriguez and Acosta 1997, Rodriguez,et al.1999). N-hydroxy-DAK is
susceptible to further FMO-mediated oxidative assaults, where it has been
speculated toxic and reactive metabolites could be creating a primary
hydroxylamine, a nitrone, and an oxime whereas KT could be responsible, in part,
for the toxicity of KT (Rodriguez,et al.1999). Soft nucleophilic sulphur,
selenium, nitrogen, or phosphorus pharmaceuticals can undergo oxidative
metabolism catalyzed by FMOs (Ziegler 1988). Hydroxylamines may directly
interact with biomacromolecules to impair cellular function (Cashman, Xiong, Xu,
et al.1999). Therefore, a reduction of GSH would be expected if bioactivation of
an electrophilic metabolite such as DAK and N-hydroxy-DAK occurred due to the
conjugating nature of this cellular scavenger to preserve the integrity of the cell
(Hogberg and Kristoferson 1977b). Another possibility is DAK will undergo phase
II metabolism by sulfation and/or glucuronide conjugation, which would provide
good leaving groups resulting in a nitrenium cation that could possibly bind to
protein and DNA leading to adduct formation.
Thein vitrocovalent binding studies of KT and/or its metabolite(s)
to SD rat hepatic microsomal protein was found to be NADPH-dependent and was
inhibited by co-incubation with GSH (Figures 12 and 13). Figure 13 demonstrates
the addition of GSH in the microsomal-incubation significantly reduced the
covalent binding of KT and/or its metabolites to hepatic protein implicating GSHas an important detoxification pathway through conjugation. The 1 mM GSHin
vitro incubation with KT would prevent the formation of protein- and/or DNA-KT
adducts; thereby, possibly forming GSH-KT adducts. To dissect CYP-or FMO-
mediated bioactivation to potential reactive metabolite(s), heat inactivation of
microsomal-FMO fractions inactivated FMO activity but CYP activity remained
unimpaired (Ziegler 1980). Earlier studies of DAK employed SKF-525A,a
compound that does not affect FMO activity and inhibits CYP and octylamine,a
known positive effector for FMO and also an inhibitor of CYP (Rodriguez and
Acosta 1997) resulted in unaltered metabolism. Furthermore, in vitro activity
comparisons of DAK by implementing a pH of 7.4 (optimum for CYP)vs. 8.8
(optimum for FMO) a significant reduction occurred with the lower pH in
microsomal incubations (Rodriguez, et al. 1999). Figure 14 demonstrates with
NADPH present profound and significant reduction in KT and/or its metabolite(s)
covalent binding to hepatic protein by FMO heat-inactivation of the rat liver
microsomes. Because FMO-mediated metabolism was inhibited, it is speculated
that the metabolite(s) of KT is/are primarily responsible for the covalent binding to
hepatic proteins.
Continued efforts are being made to identify whether KT and/or its
metabolite(s) are binding to the hepatic protein and to identify the nature of the
protein adduct. Further studies are also being conducted to determineor verify the
binding of KT or its metabolites to GSH mediated by liver microsomal FMOsorindividual FMO isoforms. If a GSH adduct is formed, attempts will be made to
characterize its structure by mass spectrometry and NMR methods.
The microsomes from the pretreated Fischer rats with 1-3-C, a
compound that has been found to inhibit the FMOenzyme, produced lower peaks
for covalent binding than the SD rat microsomes. The 10 tM KT-incubation of SD
rat microsomes reached a plateau at 2 hours, with a peak and a profile that was
consistently higher than the Fischer rat microsomes. Implicatedwas a possible
inhibition imposed on the FMO enzyme by the pretreatment of 1-3-C in the Fischer
rat. Possibly, if implementation of the higher concentration of 100 1M had been
utilized for comparison, an increased difference would have been observed.
To evaluate the role of microsomal-FMO bioactivation of KT to
reactive metabolite(s) that may bind to hepatic protein, heat inactivation of
microsomal-FMO was performed. Microsomal-FMO activity was inhibited by
heat-inactivation of the microsomes at50 Cfor 90 seconds, which is an
established method to dissect FMO- and CYP-microsomal activity (Ziegler1980).
Reportedly, heat inactivation pretreatment does not affect CYP (Kedderis and
Rickert1985).Figure 14 indicated the effect of heat inactivation onin vitro
covalent binding of 100 tM 3H-KT (1 iiCi/mL) by a >4-fold reduction by the8-
hour time point.
Due to a decrease inin vivohepatic GSH levels,in vitrocomparative
analyses utilizing 1 miVi GSH (Cribb,et al. 1991,Pirmohamed,et al. 1995)in
microsomal incubations were conducted to determine whethera reduction ofcovalent binding to hepatic proteins would occur. GSH has been found to bean
important protective factor by decreasing protein binding in hepatic microsomal
fractions therefore reducing associated toxicity (Gao, et al. 1996). Becausea
reduction in covalent binding occurredinvitro with heat inactivation or the
addition of GSH experimental analyses were implemented utilizing both
procedures for comparative analysis represented in Figures 15 a and b, and 16.
The final analysis indicated the highest reduction in covalent binding with
implementation of both procedures.
In summary, these studies support that KT-induced hepatotoxicity is
dose- and time-dependent and appears to be dependent, in part,upon its
bioactivation by FMO to metabolite(s), due to the reduction of covalent binding
observed with heat inactivation, that may react with protein and possibly, GSH.
Thus, our combinedinvitro studies andin vivostudies point to potential
mechanisms of KT-induced hepatotoxicity that merit further investigation.
Mechanistic information regarding the hepatic microsomalmonooxygenase
mediated covalent binding of KT to proteins was implicated in this study.
Mechanistic profiling is a necessary component in drug administration "Adverse
drug reactions are common and a significant cause of morbidity and mortality"
(Park and Pirmohamed 2001); therefore determining metabolic pathways thatcan
be utilized for efficacy and minimize toxicological effects is vital. Drug induced
toxicities cause toxicity by covalently altering cellular macromolecules leading to
enzyme inactivation, altered functions of structural proteins or transcription,disruption of intracellular calcium homoeostasis, loss of cellular membrane
integrity due to lipid peroxidation or apoptosis (Pohl, et al. 1996). Patients taking
drugs that induce the mixed-function oxidase system are at risk for co-
administration including over-the-counter drugs such as acetaminophen due to
potential hepatotoxicity (Simon 1992). Therefore, qualitative predictions are
dependent upon knowledge of the enzyme specificity for a substrate based upon
chemical structure that can be readily utilized for future application.[174
CHAPTER 3: FMO DETECTION IN THE HUMAN iNTESTINAL
TRACT AND CACO-2 CELL LINE
3.1. ABSTRACT
This study investigated the presence of the flavin-containing
monooxygenase (FMO) isoforms FMO1, FMO3, and FMO5 within the human
intestinal tract, which may be responsible for first-pass metabolism, decreased
bioavailability, or bioactivation of xenobiotics. Comparative western blot analyses
utilizing polyclonal primary antibodies and goat-anti-rabbit secondary antibodies
coupled with chemiluminescence were conducted with microsomes from human
jejunal mucosa, duodenal tissue, ileum, colon, and Caco-2 cells. Densitometry of
the bands followed by quantitative analysis were performed to evaluate FMO
protein expression. FMO1 protein, 58 kDa,was detected in all samples. There
appeared to be inter-individual variability of FMO1 within the human samples,
54.2 ± 20.7 pmol FMO1/mg protein and 14.98 ± 9.94 pmol FMOI/mg protein in
human jejunum and Caco-2 cell line, respectively. FMO3 and FMO5were not
detected in any of the human samples. The level of FMO1 protein from the human
jejunum samples inversely correlated with age (p <0.05). In the FMO1 westerns,
there were non-specific immunoreactive bands observed with the FMO1 primary
antibody at the 40 kDa and 65 kDa. N-glycosylation studieswere performed to
determine if the 65 kDa band was glycosylated FMOI. A band shift to the 58 kDa
species following endoglycosidase H treatment of microsomes suggested that the
65 kDa band is glycosylated FMOI protein. However, resultswere variable in theduodenal tissue and jejunal mucosa microsomal preparations. These findings
indicate that FMO1 is present in human duodenum, jejunum, ileum, and colonas
well as the Caco-2 cell line, which may be responsible for the low bioavailability
of drugs that are substrates for FMO1. Studies to determine the activity of FMO
still remain to be conducted.['11
3.2. INTRODUCTION
The major oxidative monooxygenase phase I enzymes are
cytochrome P450 (CYP) and flavin-containing monooxygenases (FMO), which
have been detected in the liver (Bonkovsky,et al.1985) and enterocytes of the
small intestine (Hall,et al.1999, Yeung,et al.2000). The most common
biotransformation reaction is oxidative phase I, which can result in significant
first-pass (Thummel,et al.1997). This contributes to the pre-systemic removal of
a drug resulting in reduced bioavailability after oral administration. Hepatic drug
metabolism was considered to be the major contributor to systemic drug
elimination, however, recent studies have shown that intestinal drug metabolism
also contributes to the first-pass effect (Hall,et al.1999). CYP is an example of
oxidative metabolism in both the liver and the mucosa of the small intestine which
can result in significant first-pass effects (Cashman 1996, Thummel,et al.1997).
FMO often shows activity toward CYP substrates (Larsen-Su and Williams 1996).
A total of five FMO isoforms have been reported (Hines,et al.2002). FMOI,
FMO2, FMO3, and FMO5 display selective substrate specificity metabolism of
soft nucleophiles, such as sulfur (S), phosphorus (P), selenium (Se), and nitrogen
(N) (Koukouritaki,et al.2002). The cDNAs encoding FMO4 have extended
coding regions. The derived sequences of human FMO4 contain 558 residues,
whereas other FMO isoforms are 535539 residues in length, thus FMO4 does
not express the same activity characteristics as other FMO isoforms unless
truncated (Itagaki,et al.1996). Also FMO1, FMO3, and FMO4 display a distinctpattern of developmental and tissue-specific expression (Dolphin 1996), possibly
contributing to organ-susceptibility to xenobiotics (Koukouritaki,et al.2002).
Variability in therapeutic responses to orally administered drugs are
often due to first-pass effects. Variations in plasma concentrations can also be due
to inter-individual therapeutic responses (Pond and Tozer 1984), which adds to the
complexity of tissue-specific FMO expression (Whetstine,et al.2000). FMO
activity may contribute to the variability of individual drug response and drug
clearance (Stormer,et al.2000). Variation in therapeutic responses can occur due
to drug-drug/drug-food interactions (Tam 1993) or polymorphism (Forrest,et al.
2001). FMO genetic polymorphisms have been characterized in FMO2 and FMO3
(Cashman 2002). Patients with mutations may exhibit an alteration in
detoxification or possible bioactivation of drugs (Krueger, Williams,et al.2002).
Absorption in the gut wall has been reported to be highest in the
duodenum and jejunum due to the increased surface area from both the plica folds
and villi-microvilli appendages. Absorption begins to decrease down the GI tract
into the ileum and colon where there are less plica folds and villi (Ilett and Davies
1982). The highest metabolizing activity is found in the pylorus and in the upper
small intestine (Caldwell and Marsh 1982, Renwick and George 1989).
Understanding the alterations in drug-metabolizing enzyme
expression and the ability to predict therapeutic dosing in order to avoid reduced
bioavailability and toxicity is difficult (Hines and McCarver 2002). It is important
to determine the intestinal enzymes and their tissue distribution in order to assessthe relative contribution of each enzyme to intestinal metabolism (Lin,et al. 1999).
A better understanding of these systems will foster optimal drug development and
therapeutic predictions (Carriere,et al.2001).
CYP3A is responsible for the metabolism of approximately 50% of
the marketable drugs currently on the market (Thummel,et al.1997). Moreover,
CYP has been detected and quantitated in the jejunum, ileum, and duodenum
(Hall,et al. 1999).While CYP has been studied in great detail over the past
decade, limited information is available regarding the human intestinal FMO.
Commonly used in pharmaceutical drug discovery, Caco-2 cells have
been characterized to be similar to the human GI epithelium including the
expression of many of the brush border hydrolases, ion transport properties and
carrier systems (Bailey,et al. 1996).Caco-2 cells have been utilized for
determinations of intestinal metabolism (Carriere,etal. 2001) and transport
studies (Lampen,etal.1998).CYP1A1, CYP2EI, and CYP3A (Lampen,etal.
1998),but CYP3A4 has been found to be at low levels in Caco-2 cells. However,
with continuous culture and induction with ict, 25-dihydroxyvitamin D,a large
increase in CYP3A4 activity does occur. A Caco-2 clone, TC7 cells, has been
shown to express after confluency higher levels of the expression of CYP3A4 in
both mRNA and protein levels (Carriere,et al.2001). CYP1AI has been found to
be highly expressed in dividing Caco-2 cells (Lampen,et al. 1998,Carriere,etal.
2001). Elucidation of FMO expression and activity in the Caco-2 cells could aid
in metabolism predictions performed at pharmaceutical industries. Functional91
FMO in the intestine could be responsible for reduced bioavailability and altered
metabolism leading to toxicity from soft nucleophiles suchas N, S, P, or Se as
seen with albendazole (F = 0.14) and chiorpromazine (F = 0.32). Therefore,
investigation of the presence of FMO isoforms and the functional activity is
warranted.92
3.3. MATERIALS AND METHODS
3.3.1. Chemicals and supplies
Dulbecco's modified eagle medium (DMEM), Dulbecco's modified
eagle medium (DMEM)/ F12 (Ham), fibronectin (human a-Chymotryptic 120K
fragment), epidermal growth factor (EGF), trypsin-EDTA, Dulbecco's phosphate
buffered saline (PBS), and MEM100X non-essential amino acids were purchased
from Gibco (Rockville, MD). Fetal bovine serum (FBS) was purchased from
Summit (Fort Collins, CO). Vitrogen (purified collagen) was purchased from
Cohesion Tech (Palo Alto, CA). Sodium hydroxide was purchased from
Mallinckrodt (Paris, KY). Sodium azide, 30% acrylamide/0.8% bisacrylamide and
TEMED were purchased from Bio-Rad Laboratories (Hercules, CA). Glycerol,
dithiothreitol (DTT), aprotinin, tris base, potassium phosphate, sodium dodecyl
sulfate (SDS), bromo phenol blue, methanol, sodium chloride (NaCl), Tween-20,
ammonium persulfate (APS) and urea were purchased from Fisher Scientific
(Fairlawn, NJ). Sodium pyruvate, antibiotic/antimycotic solution (10 mg/mL
streptomycin, 10,000 Units/mL penicillin G, 25 ig/mL amphotericin B),
oxaloacetic acid, insulin, bovine serum albumin, apo-transferrin,
phosphorylethanolamine, triiodothyronine, ethanolamine, hepes, sodium selenite,
hydrocortisone, L-glutamic acid, dimethyl sulfoxide (DMSO), sucrose,
phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail, trypsin
inhibitor, 4-amidinophenylmethanesulfonyl fluoride (APMSF), pepstatin A,
trizma, sodium ethylenediaminetetraacetic acid (EDTA), potassium chloride,93
tetrasodium pyrophosphate, tris hydrochloride, glycine, trypan blue,
endoglycosidase (Endo H), and KodakTM film were purchased from Sigma
Chemical Co. (St. Louis, MO). Ethanol (ETOH)was purchased from Oregon State
University Chemical Distribution (Corvallis, OR) and Safeway Natural Non-fat
Dry Milk was purchased from local grocery store. All solutionswere brought to
volume with double distilled water (dds).
3.3.2. Human donor and cell line material
Human duodenal tissue, jejunal mucosa, and human jejunum, ileum,
and colon microsomes were purchased from the Human Cell Culture Center, Inc
(HCCC) (Laurel, MD). Of the fourteen donors, 9 were female and 5were male.
Twelve of the donors were Caucasian and 2 were African American ranging from
3 to 59 yrs in age. Seven donors were smokers, and 12 consumed alcoholor took
prescription medications or both. The cause of death of donorswere intracranial
bleed, head trauma/stroke, anoxia, intracranial hemmorage,or myocardial
infarction.
Caco-2 cells (HTB-37) passages used in these studies were numbers
27, 29, and 31, was obtained from American Type Culture Collection (ATCC)
(Rockville, MD). Protein concentrations from microsomal preparationswere
determined with the Coomassie® Plus Protein Assay (Pierce, Rockford, IL).3.3.3. Statistical analysis
Statistical analysis used ANOVA performed by the SAS-system
8.01 .01 TS Level O1MO (1999-2000), with the Windows version 4.90.3 (SAS
Institute, Cary, NC, USA). Determinedwas the significance of FMO1 expression
as a function of age, gender, drug and alcohol consumption, ethnicity, or smoking
versus non-smoking habits of donors. Probability values of P0.05 were
considered statistically significant.
3.3.4. Culturing of Caco-2 cells
Cell seeding and maintenance (Protocol I): Seeding: Caco-2 cells
were thawed quickly at 37
OC, seeded and maintained in 25, 75, or 162cm2
polystyrene flasks (Fisher Scientific, Fairlawn, NJ). Maintenance: the cellswere
maintained at 37 C in an atmosphere of 5%CO2(Industrial Welding, Albany,
OR) and 95% relative humidity inCO2water-jacketed incubators (Nuaire model
2700/2700E Austin, TX). Caco-2 (HTB-37) cells (Protocol H): Upon receipt
from ATCC, cells were immediately seeded into a 75cm2polycarbonate flask.
Cells were fed a complete media (DMEM: F-12 (Ham) with L-glutamate, 10 %
FBS, 0.1 mM non-essential amino acids, 1:100 sodium pyruvate, and 1:100
antibiotic/antimycotic solution) every two days until harvest. For microsomal
preparations, the cells were allowed to grow one day beyond 100% confluency to
increase protein content.95
3.3.5. Microsomal Preparation
3.3.5.1. Human donor mucosa/tissue: (Protocol K)
Human donor jejunum mucosa (JM1, JM2, JM3, JM4, JM5, JM6,
JM7, and JM8) and duodenal tissue (DT1) were converted into microsomal
preparations according to the method of Lu et al. (1998) with the modification of
the addition of protease inhibitors such as aprotinin (Gobinet-Georges et al., 2000,
Kelly and Struthers, 2001), APMSF, PMSF, and the Sigma® protease inhibitor
cocktail. Briefly, the upper villus layer of the mucosawas removed with a glass
slide edge and suspended in cold potassium phosphate homogenization buffer
(PPB) (100 mM potassium phosphate, pH 7.4, 1 mM EDTA, 150 mM, 0.1 mM
DTT, 250 mM sucrose, 0.228 mM pepstatin A, 10 mg/20 mL trypsin inhibitor,
0.25 mM APMSF, 0.25 mM PMSF, 0.25 mL/20 mL protease inhibitor cocktail,
4000 KIU/total volume aprotinin). Mucosal cells were pelleted at 5000rpm
(3,440 g) for 6 minutes at 4 C (Beckman J2-HS, rotor JA17, Fullerton, CA) and
then washed with PPB. By weight, the pellet was homogenized ina 4-fold volume
of PPB and sonicated (Fisher Scientific sonicator dismembrator, Model 100,
Fairlawn, NJ) for 10 seconds. The homogenatewas pelleted at 12000 g for 30
minutes at 4 C and washed in minimal buffer (100 mM tetrasodium
pyrophosphate, pH 7.4, 1 mIVI EDTA). After washing, the buffer was centrifuged
at 30,000 rpm (100,000 g) for 15 minutes in an ultracentrifuge (Beckman L8-
70M, Fullerton, CA). Microsomes were resuspended in 0. 1M PPB (pH 7.4) with
250 mM sucrose and 1 mM EDTA. The microsomeswere then aliquoted (1mL/vial) into cryogenic vials, snap-frozen in liquid nitrogen and stored at 80 C.
A sample of each aliquot was set aside for protein determination.
3.3.5.2. Cell culture: (Protocol J)
At harvest, flasks were removed from the incubator and cellswere
washed 3 times with warmed (37C) PBS. The cells were then bathed in 2 mL of
a cold protease (0.25 mM PMSF, 0.25 mL/2OniL protease inhibitor cocktail, 10
mg/2OmL trypsin inhibitor, 0.25 mM APMSF, 0.228 mM pepstatin A) and
homogenization buffer (100 mM trizma, 1 mM EDTA, 250 mM sucrose) and
placed immediately on ice. After 5 minutes, the cellswere scraped to dislodge
cells from the bottom of the flask and then transferred to another flask ina
stepwise transference procedure until the cells from all the flaskswere combined.
After harvesting, the cells were made into microsomes. Briefly, the
cells were sheared and the cell suspensionwas microscopically observed (trypan
blue exclusion test). The cell suspensionwas centrifuged at 2200 g at 4 C for 5
minutes. The supernatant was removed from the resultant spin and centrifuged
again at 9000 g for 10 minutes. The final supernatantwas ultracentrifuged
(100,000 g, 90 minutes, 4C, Beckman L8-70M). The supematant was discarded
and the resulting pellet was resuspended in buffer (10 mM trizma, 1 mIVI EDTA,
20% glycerol, pH 7.5), transferred into cryogenic vials (0.5 mL), flash-frozen in
liquid nitrogen and stored at 80 C. A sample of each aliquotwas set aside for
protein determination.97
3.3.6. Western blot analyses: (Protocol L)
3.3.6.1. Detection FMO1. FMO3, FMO5
Vertical minigel western blot analyses (Thummel, et al. 1988) were
conducted utilizing SDS-PAGE (10% resolving gel). Briefly, the aforementioned
microsomal samples were thawed on ice. FMO1, FMO3, and FMO5
Supersomes® (Gentest Corp., Woburn, MA), purified FMO human cDNA
proteins, from an insect baculovirus system, were utilized as controls in the
experiments. Half of a microgram of each FMO protein was loaded onto the gels.
Kaleidoscope pre-stained molecular weight standards () (BioRad, Hercules, CA),
and pre-stained SDS-PAGE low range molecular weight standards (5 tL)
(BioRad, Hercules, CA) with molecular weights from 206 kDa to 7 kDa and from
110 kDa to 21.4 kDa, respectively were utilized. In all experiments, 4X loading
buffer (6 g urea, 1 g SDS, 1.2 g DTT, 100 mM tris base (pH 8.0), 1 mg/10 mL
bromophenol blue) volume was kept constant (15 !L) to avoid possible gel
migration. Loading buffer was added to the microsomal samples. The amount of
protein loaded varied among experiments. The total loading volume was 60 .tL.
Due to the low protein concentrations of the cell culture microsomes, the total
loading volume was increased to 75 !tL. Samples were boiled at 100 C for 23
minutes, placed immediately on ice, vortexed, and loaded for SDS-PAGE resolve.
FMO1, FMO3, and FMO510Ab of 1:500 and 1:1000 dilutions (Gentest Corp.,
Wobum, MA) were used with nitrocellulose (BioRad, Hercules, CA) or polyvinyl
difluoride (PVDF) (ImmobilonTM-P, VWR, Seattle, WA) membranes, pore size of0.45 cm for transference. The gel was transferred (CBC Scientific Company, Inc.,
Del Mar, CA) with transblot buffer (25 mM tris base, 192 mM glycine, 20%
MeOH), for 1 hour (100 volts). Various immunblot buffer [113] (20 mM tris base,
500 mM NaCI, pH 7.2) blocking techniques were implemented using either 3%
BSA or 1, 2, 3, 4, or 5% powdered milk and 2° Ab adjustments of 1:2000 to
1:10,000 dilutions were used to reduce the non-specific binding. After the10and
2° antibody incubations, the membranes were washed with IB-0/05% Tween 20,
1° and 2° antibody incubations, and washings were conducted on a rotating shaker
(Labline Rotator, model 1314, Melrose Park, IL). Bands were detected by
autoradiography with ECL (Amersham Pharmacia, Sunnyvale, CA) or Immunostar
chemiluminescence (BioRad Laboratories, Hercules, CA).
3.3.6.2. FMO1 detection:Human donor microsomes
Microsomal samples of the human duodenum (donor DT1), jejunum
(donors Ji, J2, J3, J4, J5, J6, J7, J8, J9, J10, Jil, JM1, JM2, JM3), ileum (donor
Ill), and colon (donor Cli) were utilized in several western blot analyses. FMO1
and FMOS (0.5g) as the positive and negative controls, respectively, molecular
markers, and microsomal samples of the jejunum, ileum, duodenum, or colon (75,
100, or 50 rig) were evaluated on each gel.
Nitrocellulose or PVDF membranes were used for comparison due to
high background noise with the nitrocellulose membrane. The nitrocellulose
membrane was blocked for 30 minutes with BSA in lB and exposed to the FMOI10Ab (1% BSA- lB. 1:500) overnight at room temperature. The following day,
the membrane was washed 3 times (20 minutes each) and exposed to IgG-alkaline
phosphatase 2° (1:2000) (Biorad Laboratories, Hercules, CA) for one hour at room
temperature. After five washings of the membrane, 1 mL of the
chemiluminescence (Immunostar) reagent was applied to the membrane and
exposures were conducted. Timed exposures were from 30 sec to 45 minutes,
dependent upon signal clarification. The PVDF membrane was blocked for 30
minutes with 1%, 2%, 3%, 4%, or 5% powdered milk in IB, exposed to 1° Ab-IB
concentrations of 1:500 to 1:1000 dilutions, with 0.5% powdered milk for 2, 3, or
4 hours. PVDF membrane washings after 1° and 2° Ab were as with the
nitrocellulose membrane, however after the 2° Ab the washings were reduced to
three instead of four. Secondary Ab (1:2000 to 1:10,000) was anti-rabbit
horseradish peroxidase (Gentest Corp., Woburn, MA) in lB with 0.5% powdered
milk. A membrane comparison was conducted to determine if the lB conditions
with either BSA or powdered milk would reduce the non-specific binding so an
adequate assessment of the FMO protein signal could be determined.100
3.3.6.3. Caco-2 cell microsomes
Western blot analyses of microsomal Caco-2 cells were conducted
with FMO1 and FMO5 as the positive and negative controls, respectively as well
as a colon (donor Cli) sample as a second positive control. Microsomal samples
of 75, 100, 150, or 300 tg protein were evaluated.Blotting was performed with
either nitrocellulose or PVDF membranes. The procedure was identical to that
described in 3.3.6.2. and a 2° Ab concentration of 1:2000 was used. Microsomes
were prepared Caco-2 cell passages 27, 29, and 31.
3.3.6.4. Immunoprecipitation: (Protocol M)
Immunoprecipitation was conducted to form an antigen-antibody
complex with FMO1 and the FMO1 primary antibody in an attempt to collect only
the FMOI protein and remove unwanted contaminants. This procedure could aid
in reducing background noise. Immunoprecipitation experiments were conducted
using the human jejunal microsomal samples Ji, J3, and J9 loading 300 tg per
lane. Increased protein concentrations were used to increase the probability of the
antibody complexing with the antigen. Briefly, samples (300g) were diluted
with 0.5 mL of 2.5% triton dilution/homogenization buffer with 2.5% Triton X-
100, 0.2% protease inhibitor cocktail to homogenization buffer (100 mM trizma,
250 mM sucrose, 1 mM EDTA, pH 7.4).Samples were tumbled on a rotary
platform for 1 hour, centrifuged, and the resultant supernatant was tumbled with
FMOI 1° Ab (1:500) overnight at 4 ° C. The following day, 50 tL from a PAS101
(50%) slurry (75 mg PAS/0.6 nil, homogenization buffer), for complex formation
was added to each sample and incubated for 1 hour at 4 ° C. Samples were
centrifuged (14,000 rpm) for 4 minutes to obtain a pellet. Supernatant was
removed and each sample pellet was washed (vortexed) 4 times with an equal
volume (1 mL) of 2.5% triton dilution/homogenization buffer and the pellet was
resuspended and briefly centrifuged for 5 mmat 14,000 rpm. Then, the pellets
were washed with homogenization buffer without detergent twice, centrifuged, and
the resulting supernatant was discarded. Samples were boiled for 2 to 3 minutes,
pelleted at 14,000 rpm, and the supernatant was utilized for resolve. FMO1 and
FMOS were utilized as the positive and negative controls, respectively. Individual
samples of FMO1 were run with and without PAS, and FMO5 contained PAS.
3.3.6.5.N-glycosylation
When conducting the de-glycosylation experiments, there was a
slight modification in the western blot sample preparation. Briefly, the
microsomes from human jejunal mucosa, JM1, JM2, JM3, and human duodenal,
DT1, were prepared as previously described in the western blot instructions. After
the samples have been boiled with 4X buffer and resuspension buffer, the samples
were allowed to cool and then transferred to disposable glass vials. Endo H (1
mi1liunit/!tL) and 50 mIvi potassium phosphate buffer (pH 5.5) were added to each
sample (60 tL) for a total volume of 120 L. The vials were capped with paraffin
film to avoid evaporation and incubated for 20 hours at 37 ° C in a water bath or102
cell culture incubator. After 20 hours the samplewas centrifuged (14,000 rpm) for
5 minutes. The pellet and supernatantwere separated into individual eppendorf
vials. The supernatant was loaded for resolve withoutany additional preparation.
The pellet was combined with a prepared 4X buffer and resuspension buffer
solution as per western blot instructions (Protocol L) and resolved.
3.3.6.6. FMO3/FMOS detection: human donor microsomes/cell lines
Western blot analyses were conducted for detection of FMO3 and
FMO5 in human jejunal microsomes and microsomal Caco-2 cells. Jejunum (JI,
J2, J3, J4, J5, and J6), colon (C 11), and Caco-2 cell (pass 27, and 29) microsomes
were utilized. The positive and negative controls of FMO1, FMO3 and FMO5,
were resolved on separate blots with indicated samples. Total microsomal protein
loading was 150 tg/lane for the human jejunum and colon microsomes, and 300
tg/lane for Caco-2 cell microsomes. Nitrocellulose membrane andexposure to
alkaline-phosphatase10Ab and chemiluminescence was performed with an
Immunostar kit as previously described in section 3.3.6.2.103
3.4. RESULTS WESTERN BLOT ANALYSIS
3.4.1. FMO1 in human donor microsomes
Figures 18, 19, and 20 indicated the presence of FMO1 with
chemiluminescence on a nitrocellulose membrane utilizing microsomal samples
from the human donor jejunum (JI, J2, J3, J4, J5, J6, J7, J8, J9, J10, and Ji 1),
ileum (Ill), and colon (Cli). FMO1, 58 kDa, levels injejunum ranged from 29.8
to 88.6 pmol FMO1/mg protein. The average FMO1 protein concentration in
human jejunal microsomes (16 samples, performed in duplicate) was 54.2 ± 20.7
pmol FMO1/mg microsomal protein. The highest and lowest protein
concentrations were 88.6 pmol of FMO 1/mg protein from a 27 yr African
American male (donor J9-Figure 19) and 29.9 pmol of FMO 1/mg protein from a
40 yr Caucasian female (donor Ji 1-Figure 19), respectively. FMO1 protein levels
detected for the youngest and the oldest donor ages were 44.8 pmol FMO 1/mg
protein from a 3 yr African American male (donor J5-Figure 18) and 35.8 pmol
FMO 1/mg protein from a 59 yr Caucasian male (donor JM2-Figure 20),
respectively.
Shown in Figures 18, 19, and 20 is non-specific binding of FMO110
antibody at 40 kDa and 65 kDa. Figures 18 and 19 represent Ji, J2, J3, J4, J5, J6,
J7, J8, J9, J10, and Ji 1 (150 tg) and Figure 20 represents JM1, JM2, and JM3
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Figure 18: FMO1 western blot nitrocellulose detection in human donor jejunum microsomes. Depicted are
FMO1, 0.5 pg and FMO5, 0.5g as the positive and negative controls, respectively. Microsomal protein
loading was 150 tg/lane. The 58 kDa arrow represents the apparent molecular weight for FMO1.
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Figure 19: FMO1 western blot nitrocellulose detection in human donor jejunum microsomes. Depictedare
FMO1, 0.5 tg and FMO5, 0.5 ig as the positive and negative controls, respectively. Microsornal protein
loading was 150 pg/lane. The 58 kDa arrow represents the apparent molecular weight for FMOI.58 kDa
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Figure 20: FMO1 western blot nitrocellulose detection in human donor jejunum microsomes. Depicted
are FMO1, 0.5 tg and FMO5. 0.5 jtg as the positive and negative controls, respectively. Microsomal protein
loading was 100 pg/lane. .The 58 kDa arrow represents the apparent molecular weight for FMO1.107
Figure 21 a displays the variation of pmol of FMO 1 according to age of
donors and Figure 21b represents the averages of the donors according to < 36 yr
and > 36 yr. A significant difference was seen with increasing age where there was
a decrease in the amount of detectable FMO1 (ANOVA, p <0.05, n = 12).
Averages according to age revealed <36 yr 68.6 ± 21.5 pmol FMO1/mg protein and
>36 yr 37.9 ± 6.1 pmol FMO1/mg protein. The 3 yr and 12 yr donors were not
utilized for statistical analysis due to developmental factors. Table 6 depicts
information regarding each individual donor and their cause of death.a)
b)
100
.E90 2s)35+) 0 2fr) 80 12
70 17s+)
60
50
40 37(s+) 57(.) o 23(s+) 52(+)57(s+)
59(+) E 30
40(i-) 20
10
0
30 40 50 60 70 L _____
Age of donors (years)
<36 >36
AGE (years)
Figure 21: Comparison of pmol of FMO1/ mg of protein in human donor jejunal
microsomes. (p <0.05, n=12) a) Numerical values of individual locations are
representative of age in years. Also represented are whether the donor wasa
smoker by the letter "s" or alcohol/prescribed medication consumption bya
sign listed next to the respective age of the donor. b) The average and standard
deviations of donors <36 yrs of age and donors >36yrs of age.109
Table 6: Donor Information. Abbreviations are as follows: ICB-intracranial
bleed; CHI-head trauma/stroke; ICH-intracranial hemorrhage; HT-head trauma;
MI-myocardial infarction; NIIDM-non insulin dependent.
Donor Age
Caucasian (C)
African American (A)
Male (m) Female (1)
(donor identification)
Smoker
versus non-
smoker
Ingestion of
alcohol!
medication
Pre-existing illnessCause
of
death
57C f (Ji) + + emphysema, ulcerICB
12C f (J2) - CHI
35C f (J3) + + Anoxia
43Cm(J4) - + ICH
3B m (J5) - - Anoxia
23 Cf(J6) - + HT
37C m (J7) + + hypertension ICH
17C f (J8) + + anorexia CHI
27Bm(J9) + + CHI
57C f (J1O) + + border diabetes ICB
40 C f (Ji 1) - + asthma CHI
23C f (JM1) + + asthma Anoxia
59 C m (JM2) - + NIIDM (16 years)
hypertension
MI
52 C f (JM3) - + asthma, arthritis Anoxia110
Figure 22 indicates the presence of FMO1 in the human jejunum,
ileum, and colon (donor 11) on a nitrocellulose membrane. The analysis of band
intensity indicated 60.9 pmol FMO 1/mg protein in the human jejunum, with the
ileum and colon comparable at 53.1 and 54.3 pmol FMO 1/mg protein,
respectively. Donor Ji 1 was also analyzed previously, shown in Figure 19,
resulting in the lowest protein concentration detection of 29.9 pmol of FMO 1/mg
protein. Therefore, intra-variability was indicated.58 kDa
Figure 22: FMO1 western blot nitrocellulose analysis from human ileum, jejunum and colon
microsomes. FMO1 (0.5 .ig) and FMO5 (0.5 .ig) as the positive and negative controls, respectively.
Microsomal protein loading was 150 j.tlane. The 58 kDa arrow represents the apparent molecular
weight of FMO 1.112
3.4.2. Immunoprecipitation and N-glycosylation
Immunoprecipitation was utilized to form an antibody-antigen
complex to avoid non-specific binding results. In these experiments, the pellets
were difficult to visualize during the washing process and appeared fragile,
therefore it is probable part of the pellet was being lost. Experiments produced
variable results from a faint band at approximately 58 kDa to a definite band with
a stepladder visual throughout the individual sample lane for the human jejunum
samples. Because high background signaling was also present, these results were
inconclusive.
In order to determine if the 65 kDa band was the glycosylated form of
FMO 1, de-glycosylation experiments were conducted using microsomes prepared
from duodenal tissue (DT 1) and microsomes from jejunal mucosa (JM 1, JM2,
JM3). The western blot experiments indicated the possibility of the presence of N-
glycosylation in FMOI. Duodenal microsomes indicated susceptibility to de-
glycosylation because the 65 kDa signal in the duodenum sample that had been
present in previous experiments was absent with the presence of endo H. The
jejunum 65 kDa non-specific binding in previous experiments was reduced toa
faint band. Further experiments were variable in jejunum samples. The strongest
evidence for N-glycosylation detachment due to a verifiable signal at the FMO
molecular weight of 58 kDa and an obvious absence of the non-specific binding at
65 kDa was in the supematant samples, whereas the pellet signal for FMO at 58113
kDa was indiscernahie for verification. It appears the FMOI protein was present
in the supernatant after the de-glycosylation with endo H (data not shown).
3.4.3. Caco-2 cell microsomes
Figure 23 indicates the presence of FMO 1. Western blots using the
nitrocellulose and PVDF membranes were conducted. Band intensity was
determined with alkaline-phosphatase chemiluminescence autoradiography
followed by densitometry analyses. Each sample exposure contained 300pg of
protein. The presence of FMO 1 was detected from the Caco-2 cells microsomes,
but there was a high background signal and non-specific binding which were
inconclusive. With the PVDF membrane, the background was reduced, but the
apparent non-specific binding was still prevalent except with the 2 to 5%
powdered milk blocking. With a 2% powdered milk blocking, the background
was reduced and an immunoreactive FMO 1 band at 58 kDa from the Caco-2
microsomal samples was present. Microsomal preparations of pass 27, 29, and 31
of two separate western blot experiments totaling five samples
immunoquantitatively produced an average of 14.98 ± 9.94 pmol FMO 1/mg
microsomal protein. The results ranged from 2.2 to 25.1 pmol FMO1/mg protein,
with the strongest signal from pass 29 shown in Figure 23. However, there were
bands of non-specific binding. Both membranes PVDF and nitrocellulose
indicated a FMO1 signal from the Caco-2 microsomes.58 kDa
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Figure 23: FMOI western blot detection in Caco-2 cells on a PVDF membrane. FMOI (0.50 j.tg-positive control);
colon donor #11, JC11, (150 jig - positive control); Caco-2 passage 27, 29, and 31(300 jig); standard curve of FMO1,
0.25, 0.15, 0.10 jig; FMO5 (0.50 jignegative control).115
3.4.4. FMO3IFMO5 in human donor microsomes
Figures 24 a and b shows that FMO3 and FMO5, with a
nitrocellulose membrane and IgG-alkaline-phosphatase detection, are not present
in the human microsomal intestinal samples Ji, J2, J3, J4, J5, J6. Figure 26a
utilized FMO3 and FMO5 for positive and negative controls, respectively, and
Figure 26b utilized FMO5 and FMO1 as the positive and negative controls,
respectively in human jejunum donor sample microsomes Ji, J2, J3, J4, J5, and J6.
Microsomal protein samples were loaded with 150 tg per lane as with previous
western blot analyses of FMOI. Also Caco-2 cell passage 27, and 29 microsomes
indicated a negative detection of FMO3 and FMO5 protein (data not shown).a)
FMO3
FMO5
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Figure 24: FMO3 and FMO5 western blot detection in human donor jejunal
microsomes. Samples are Ji, J2, J3, J4, J5, and J6, utilizing 150tg per lane.
a) FMO3 detection. FMO3, 0.5 tg and F'M05, 0.5tg are the positive and
negative controls, respectively. Indicated in each microsomal sample is the
absence of FMO3. b) FMO5 detection. FMO5, 0.5ig and FMO1, 0.5 tg as the
positive control and negative controls, respectively. Indicated in each microsomal
sample is the absence of FMO5.117
3.5. DISCUSSION
Phase I metabolism of oral drugs may result in reduced
bioavailability, diminished efficacy or toxicity. Elucidation of specific
enzymes/isoforms involved in metabolic reactions and determination of xenobiotic
inter- and intra-metabolism variability is essential for prediction of bioavailability
and therapeutics (Hodgson,etal. 1995). Alteration in the relative amounts of FMO
compared to CYP could result in seriousconsequences for toxicological or
therapeutic properties (Williams,et al.2001).
This study investigated the presence of the FMOI, FMO3, and FMO5
isoforms within the human intestinal tract and in the Caco-2 (HTB-37) cell line
using microsomal preparations. Microsomal preparationswere selected for all
experimental analyses due to their stability for repetitive analysis. Hallet al.,in
1999 found that mucosa microsomal preparationswere reliable in detection of the
intestinal CYP3A. FMO 1 was present in all of the donor samples and Caco-2
(HTB-37) cell line (Figures 18, 19, and 20), but FMO3 and FMO5were not
detected in any of the samples.
The expression of FMO1 was highly variable in the human jejunum
at 54.2 ± 20.7 pmol FMOI/mg protein. This is comparable to the adult kidney
which has been detected at a concentration of 47 ± 9 pmol/mg protein (Yeung,et
al. 2000) and comparable to the adult liver for FMO3 detected ata concentration
of 60 ± 43 pmol/mg protein (Overby,et al.1997). This type of variability is seen
with intestinal CYP3A4. For example, CYP3A4 protein expression with human118
intestinal microsomes was variable between regions witha median and range of 31
(<2 91), 23 (<2 98), and 17 (<2 60) pmol/mg protein, detected in duodenum,
jejunum and ileum, respectively (Thummel,etal. 1997). Also, an eleven-fold
range was detected in 20 human duodenal punch biopsies of CYP3A4 protein
(Lown,etal. 1994) and total detectable content of CYP3A found within the small
intestine has been estimated at 70 nmol, the majority found in the jejunum (Hall,et
al. 1999).
Statistical analysis was conducted regarding comparable differences
in donors. The data depicted in Figure 21a indicates thatage was a significant
factor (p <0.05, n = 12, Figure 21b) that can be attributed to the inter-individual
variability. With increasing age, a reduction in the amount of detectable FMO1
protein occurred. Whether this observation is an indication of FMO1 activity
remains to be determined. FMO activity is not markedly dependentupon age or
gender in adults (Cashman 1996), however decreased levels ofa major oxidative
enzyme could produce less activity, lead to toxicity due to a decline in first-pass
metabolism and an increase in systemic concentrations. An improved
understanding of the metabolic alterations associated with aging could be essential
for the development of therapeutic interventions. Also, witha number of the
donors being smokers, possibly a discernable alteration in FMO1 protein
expression would be observed due to metabolism of nicotine by FMO 1 and FMO3
(Cashman 2000). However, the statistical analysis did not indicatean alteration in119
FMO 1 expression due to smoking. No other discernable patterns such as gender,
drug and alcohol consumption, or ethnicity were observed.
The 3 yr donor indicated an intermediate amount of FMO1 (44.8
pmol FMO 1/mg protein), which could possibly be explained as due to
developmental factors. For example, FMO1 and FMO3 mRNA in the liver is
subject to developmental regulation which will effect protein expression (Gasser
1996). Also, it has been shown that there is an incremental decrease in FMO1 and
increase in FMO3 that occurs from neonates, 111 yr followed by an increase to
18 yr (Hines and McCarver 2002). Possibly developmental regulation may have
been attributable to the findings in the 3 yr donor, however the 12 yr displayed
comparable adult readings.
Preliminary FMO analysis of carbohydrate attachment has indicated
that FMO1 in pig contains complex oligosaccharides linked to high-mannose
oligosaccharides. Sequences that have been derived from the pig FMO1 cDNA
have predicted two putative sites of N-glycosylation. Glycosylation, found in pig
FMO 1 is specific and not random, therefore, suggested is a structural purpose for
the N-glycosylation in pig FMO1 (Korsmeyer,et al.1998). Due to ortholog
identities of FMOs between species (8189%, Hines,et al.1994), and with a
strong signal at approximately 65 kDa, microsomal samples were treated with
endo H to determine whether an N-linked high-mannose oligosaccharides
attachment was present in human FMO1. Endo H will hydrolyze and digest an N-
linked glycoprotein attachment. Indicated was the presence of a sugar attachment120
that could be removed. Duodenal microsomes indicated thepresence of a glycan
moiety, but jejunal microsomal results were variable. In the jejunum microsomes,
the 65 kDa signal was decreased with endo H treatment, however the band didnot
completely disappear as in the duodenal microsomes. This suggests there isa
glycosylation present in the jejunum microsomal FMO1, but with repeated
experiments with the jejunum the signal variedas to visual intensity. It has been
speculated that even if a carbohydrate attachment is present, the N-glycosylation of
FMO1 would not grossly alter the enzyme function (Korsmeyer,et al.1998).
Cellular models have become an instrument for increasing our
knowledge of pharmaceutical potentials for an effective and rapid approach for
delivery of new therapeutics to the patient (Bailey,et al.1996). The Caco2 (HTB-
37) cell line is one of the model systems utilized for support in drug discovery
early in the process of pharmaceutical development. Determination of the
presence of a phase I enzymes such as FMO would be advantageous for an
understanding of metabolite formation. The chemiluminescence results for the
nitrocellulose and the PVDF membranes indicated the presence of FMO1 in the
Caco-2 cells (Figure 23). The PVDF membrane reduced background and revealed
an FMO 1 band in cell passage 29. The detection of FMO would add increased
credibility to future studies conducted with the Caco-2 cell line.
With discovery of substrates being metabolized by either or both
CYP or FMO are increasing (Williams,et al.2001), detection and quantification
of specific intestinal FMO isoforms and their substrate specificity and catalytic121
activity would be useful in future predictions of oral drug efficacy. This study
provided information regarding FMO isoforms and the presence of EMOI in the
intestinal tract and the Caco-2 (HTB-37) cell line. With activity determinations,
predictable responses of drugs regarding bioavailability and therapeutics as well as
toxicological effects could be assessed.122
CHAPTER 4: CONCLUSION
In summary, the studies conducted were to investigate a phase I
oxidative enzyme, FMO. The first study was to determine whether FMO could be
responsible for toxicity effects with the administration of an oral azole antifungal,
KT utilizing both in vivo andin vitromethodology for comparative analysis. The
second study analysis was to determine the presence of FMO isoforms in the small
intestine and Caco-2 cells.
In the first study observed with KT administration, a covalent
binding occurred that was correlated with increased serum levels of a hepatic
cytosolic enzyme (alanine aminotransaminase) and a reduction of a hepatic
oxidative scavenger (glutathione). These occurrences supported a relationship
between metabolism, toxicity, and covalent binding. The parent compound was
found to be suspect for a covalent binding effect, and a bioactivation of the parent
compound was also indicated. The metabolic pathway implicated was FMO-
mediation due to a reduction in covalent binding with heat inactivation analysis.
FMO is heat labile. Drug induced toxicities are often caused by covalently
binding to cellular macromolecules leading to enzyme inactivation, altered
functions of structural proteins or transcription, disruption of intracellular calcium
homeostasis, loss of cellular membrane integrity due to lipid peroxidation or
apoptosis (Pohi,et al. 1996).123
The second study used human donor intestinal microsomes to
determine the quantitative presence of FMO isoforms that could be available for
altered pharmacokinetics and pharmacodynamics ofa compound. Indicated in
these findings was the presence of FMO 1 in the human duodenum, jejunum,
ileum, and colon. Also, detection analyseswere conducted using the Caco-2 cell
line at passages 27, 29, and 31. However, FMO3 and FMO5were not detected in
any of the samples used for FMO1 detection. Caco-2 cells are utilized for
determinations of intestinal drug metabolism with phase I oxidation (Carriere,et
al. 2001). This study is the first to report FMOI present in the colorectal cells and
with the elucidation of FMO expression in the Caco-2 cell line, newly acquired
soft-nucleophilic compounds containing sulfur, nitrogen, phosphorusor selenium
could be tested for metabolite formation that would aid in predictable
determinations of metabolism and toxicological effects.
Both studies revealed insightful information regarding FMOs. With
oral administration of FMO substrates, thepresence of FMO could alter predicted
bioavailability and therapeutics or result in toxicity effects. Understanding ofan
enzymatic system, its location, prevalence, and inherent affinity fora particular
compound family are all useful tools for aiding in a predictable outcome of future
xenobiotics. These findings implicated FMO may play a significant role in drug
metabolism and in the future may be considereda formidable enzyme.124
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APPENDICES146
PROTOCOL A
Covalent binding protocol for in vivo analysis in Sprague Dawley rats
Objective: The procedure for an analysis of a hepatic covalent binding effect
resulting from the acute administration of ketoconazole (KT) in vivo to Sprague
Dawley rats.
Equipment:
Metabolic cages
Needles 30 ½ G (Becton Dickson 305125)
3cc syringe (Becton Dickson 5585)
Scintillation vials (7 mL) (Fisher 03-337-1)
vortexer (Fisher 12-812)
scale (Mettler PN323)
centrifuge (Eppendorf 541 5C)
oven (Beckman, Model TJ-6, VWR Scientific Inc. 1340)
disposable glass vials(13X100 mm, Fisher-Scientific 14-961-26)
eppendorf® tubespolypropylene (Fisher 2.0 mL, 05-408-255)
plastic pipet tips 1 mL, 200 iL (Fisherbrand Redi-tip 21-197-8E)
glass homogenizer and pestle (10 mL)147
Reagents
homogenization buffer, pH to 7.5 with 1 M sodium bicarbonate (NaHCO3)
(Fisher S233-3)
V 100 mM trizmaor trizma hydrochloride (Sigma T-7-149)
V 1 mM ethylenediaminetetraacetic acid (EDTA) (Sigma E-5134)
V 250 mMsucrose (Sigma S-7-903)
0.6 M and 0.9 M trichioroacetic acid (TCA) (Sigma T-639, Fisher A322-
100)
80% methanol (MEOH) (HPLC grade Fisher A457-4)
1 N sodium hydroxide (NAOH) (Malinckrodt 7708un1823)
glacial acetic acid (Fisher Scientific A35 500)
scintillation fluid (ICN Cyto ScintlM 882453)
70% ethanol (ETOH) (Oregon State University Chem Store 6061-00)
Coomassie® Plus Protein Assay (Pierce 23236)Instructions for injecting animals and harvesting liver
1. Prepare doses of 40 and 90 mg/kg and bring dose to room temperature.
2. Inject rat with interperitoneal (i.p.) injection of 3H-KT (1 .5Ci/mg).
3. Place rat in metabolic cage for allotted time point and obtain urine
samples.
4. Sacrifice rat in a CO2 chamber.
5. Use ETOH to sterilize stomach, make incision from lower part of
stomach to upper part of sternum creating a circular opening.
6. Remove liver, cut a small section (-1 gm) from liver, and remove heart
and kidneys.
7. Place liver, small section of liver, heart and kidneys in separately
labeled containers.
8. Indicate: date, body part, dose used, and time point on container.
9. Snap-freeze in dry ice, store at 20 C for later analysis.
10. Collect urine and feces from cage and urine collector.
11. Clean cage, take wipe test of cage and work area to check for
radioactive contamination.
Instructions for homogenization of liver tissue
1.All work should be conducted on ice at 4 ° C at all times.
2.Blot liver with Kim Wipe to remove excess blood for accurate weight
analysis of liver section.149
3. Weigh 1gm and deposit into glass homogenizer, with small amount of
homogenization buffer. Homogenize until all tissue is suspended.
Vortex.
4.Transfer to disposable glass tubes and vortex.
5.Pipet in 2 ml. of 0.9 M TCA into clean glass tube, add 1 mL aliquot of
homogenate, vortex, reserve 50 tL for protein concentration analysis.
6.Place all homogenate tubes into pre-cooled (4C) centrifuge for 10
minutes at 1000 g for pelleting of homogenate. Discard supernatant.
7.Pipet 0.6 M TCA onto pellet, vortex. Centrifuge 3 minutes and discard
supernatant. (Repeat 2 times).
8.Pipet 80% MEOH onto pellet (3 mL), vortex, centrifuge, discard
supernatant. This procedure should be done 3 times each time
discarding the supematant except a radioactivity reading should be
conducted on the last supernatant to insure background levels only.
9.Pipet onto pellet 1 ml. IN NAOH, vortex, place in oven at 60 ' C until
pellet is dissolved.
10. Pipet 300 tL into each vial containing 2.75 mL of scintillation fluid
(1:9) with glacial acetic acid (FisherASO7-500) (150 tL per 10 mL of
scintillation fluid).
11. Determine radioactivity reading using scintillation counter and protein
concentration by Coomassie® Plus Protein Assay (Pierce).150
PROTOCOL B
Alanine aminotransaminase (ALT) assay:
Objective: To determine the release of the hepatic enzyme ALT indicating
damage to the liver has occurred. In this assay, ALT catalyzes the conversion of
aipha-ketoglutarate and alanine to glutamate and pyruvate.
Equipment
Centrifuge (Eppendorf 5415C)
Spectrophotometer (SpectraMax 190, Sunnyvale, CA)
96-well plates (Falcon 35-3072, polystyrene, Beckton/Dickson)
Disposable test tubes (13X 100 mm, Fisher-Scientific 14-961-26)
Reagents
Sigma Diagnostic Kit (505-P)
1.Prepared substrate (Sigma 505-1)
(DL-asparate (0.2 mol/L)
s/cx-ketoglutarate acids (1.8 nmolIL)
Vin phosphate buffer (pH 7.5) (Fisher P250-500)
Vstoreat2-6°C
2.Color reagents (Sigma 505-2)
V2,4-dintrophenyihydrazine (DNP) (20 mg/dL)
Vstoreat2-6°C151
3.Calibration solution for transaminase (Sigma 505-10)
Vsodium pyruvate (1.5 mmol/L) (pH 7.5)
V'chloroform as a preservative
v'Storeat2-6°C
4.Alaninex ketoglutarate substrate (Sigma 505-5 1)
V'DL alanine (0.2 mol/L)
V'Ketoglutarate acide (1.8 mmolfL)
in phosphate buffer (pH 7.5)
Vchloroform as a preservative
Vstoreat2-6°C
0.4 N sodium hydroxide (NaOH) (Malinckrodt 7708un 1823).
0.9% sodium chloride (normal saline) (Sigma S3014) in double distilled
water (dds) (Bamstead/Thermolyne D741 1 Easypure UF).
Instructions
1.Collect blood samples at designated time points.
2.Place on ice immediately and allow for coagulation.
3.Centrifuge 8000 g at 4C.
4.Collect serum and keep on ice.
5.Assay samples with kit.
6.Prepare calibration curve of ALT activity in units/mL from serum
samples.152
7.Pipet into test tube alanine aipha-ketoglutarate (0.25 mL) in water
bath at 37 ° C.
8.Pipet in 5 tL of serum and 45 iL of normal saline.
9. Mix gently and place back into 37 C water bath for 30 minutes.
10. After 30 minutes, add 0.25 mL of Sigma color reagent (505-2),
vortex (low speed).
11. Leave at room temperature (25C) for 20 minutes.
12. Add 2.5 mL of 0.4 N NaOH, vortex.
13. Wait 5 minutes pipet 200 pL of sample mixture into 96-well plate
and measure absorbance at 505 nm.153
PROTOCOL C
In vivo glutathione (GSH) evaluation (Roberts and Francetic, 1993)
Objective: To determine total glutathione levels in rat hepatic tissue at individual
time points using low (40 mg/kg), high (90 mg/kg), anda control (saline only)
interperitoneal (i.p.) injection. Time points of 0, 0.5, 1,2,4,8, 12, and 24 hours
were used. Set absorbance reading at 412 nm.
Equipment:
Spectrophotometer (Spectromax 190, Sunnyvale, CA)
Glass homogenizer and plunger (10 mL)
96-well polystyrene plates (Falcon 35-3072, Beckton/Dickson)
centrifuge (Beckman J2-HS, Rotor JA-17)
Reagents
100 ml of 5% sulfosalicylic acid (SSA) (5 grams/100 mL)
Sample buffer:
v'100 mM potassium phosphate buffer (pH 7.5)
(Fisher P250- 500)
/5 mM ethylenediaminetetraacetic acid (EDTA, pH 7.5)
(Sigma E-5134)
Prepare in double distilled water (dds) (Barnstead/Thermolyne D741 1
Easypure UF).154
V5 units/mL (GSSG reductase) (Sigma G-3664)
V4 mg/mL 5,5'Dithiobis(2'-nitrobenzoic acid) (DTNB)
(10mM) (Sigma D-8130)
V2 mg/mL NADPH (2.4 mM) (Sigma N-1630)
.0.9% sodium chloride (normal saline) (Sigma S3014) in dds
(Barnstead/Thermolyne D741 1 Easypure UF).
Instructions
All work should be conducted on ice (4
0C).
1. Turn on centrifuge 15 minutes before work to obtain a temperature
of40C.
2. Remove liver and cut piece from liver, minimum of 50 mg. Blot
and weigh both pieces.
3. Store liver in 80
0C.
4. Homogenize the small liver piece with 5% SSA in homogenizer
tube with plunger until tissue is completely suspended.
5. Centrifuge at 3000 g for 10 minutes at 4
0C.
6. Dilute supernatant 10-fold in sample buffer.
7. Aliquot 300 L of supernatant and combine in a 1.5 mL cuvette
with 450 tL of sample buffer, 100tL of GSSG reductase solution,
and 50 iL DTNB solution.
8. Incubate for 1 minute.
9. Pipet into 100 L into reading plate in duplicate.
10. Add 100 tL NADPH solution into each well with prior solution.
11. Monitor for two minutes measuring at 412 nm the change in
absorbance per 30 seconds, start with time "0".155
PROTOCOL D
Hepatic microsomes prepared from Sprague Dawley rats:
Objective: To prepare hepatic microsomes from Sprague Dawley rat livers for
'covalent' binding analysisin vitroto determine if 'covalent' binding effects
would occurin vitroas well conduct a comparison within vivo'covalent' binding
studies.
Animals
Sprague Dawley (SD) rats, 6 to 8 weeks (Simonsen Laboratories,mc)
Equipment
biohazard disposal container
scale (Mettler PN323)
centrifuge (4 C) (Beckman J2-HS, rotor JA-17)
ultracentrifuge (4 ° C) (Beckman L8-70M, rotor J42.1 -1625)
polypropylene centrifuge tubes (2 mL) (Fisher 05-408-255)
homogenizer (ESGE Bio-homogenizer M133/1281-0)
Pipet-aid® (Drummond Scientific Co., Broomall, PA)
surgical tools: scissors, tweezers, etc.
Reagents
Homogenization buffer (pH 7.5)156
V 100 mM Trizmaor Trizma hydrochloride (Sigma T-7-149)
V 1 mM ethylenediaminetetraacetic acid (EDTA)(Sigma E-5 134)
'7 250 mMsucrose (Sigma S-7-903)
V bring to volume with double distilledwater (dds) (Mettler PN323)
Resuspension buffer (pH 7.5)
V 10 mM Trizmaor Trizmahydrochloride (Sigma T-7-149)
V 1 mM sodium ethylenediaminetetraacetic acid (EDTA)
V (Sigma E-5134)
V 20% glycerol (Fisher Biotech 56-81-5)
V bring to volume with dds
70% ethanol (ETOH) (Oregon State University Chem Store 6061-00)
Coomassie® Plus Protein Assay (Pierce 23236)
Instructions
1.Euthenize animal inCO2chamber.
2.Clean stomach area with 70% ETOH.
3. Remove liver and place in 30 mL of homogenization bufferon ice.
4. Weigh liver, place liver in 3 times the liver size of homogenization
buffer in beaker and homogenize with blender until a solution forms.
5.Pipet solution through gauze into centrifuge tubes and cap on ice.
6.Centrifuge(40C) at 8,500 rpm (10,000 g).
7. Remove white fat layer and pipet supematant through gauze into clean
centrifuge tubes obtain, dispose of pellet.157
8. Weight each tube for balancing and ultracentrifuge for 90 minutes at
30,000 rpm (100,000 g) at 4C.
9. Remove from ultracentrifuge and dispose of pellet.
10. Repeat steps 79, except keep pellet (microsomes) and discard
supernatant.
11. Remove pellet, resuspend in resuspension buffer and homogenize.
12. Snap freeze in dry ice and store at 80 ° C.158
PROTOCOL E
In vitro covalent binding analysis of Sprague Dawley (SD) and Fischer 344
hepatic microsomes
Objective: To utilize hepatic microsomes from SD rat livers for 'covalent'
binding analysis of KT/metabolite(s)in vitroto determine if 'covalent' binding
effects would occurin vitroas well conduct a comparison withinvivo 'covalent'
binding studies. Also the hepatic microsomes of Fischer 344 rats treated with
indole-3-carbinol (1-3-C) and without as the control for comparison with thein
vitrofindings of SD hepatic microsomes.
Equipment
metabolic shaking incubator (Precision Dubnoff ES722)
eppendorf® vials (2 mL volume) (Fisher 05-408-255)
centrifuge (Eppendorf 541 5C)
Reagents:
microsomal preparation
100 M potassium phosphate buffer (pH 7.4) (Fisher P250-500)
250 M ketoconazole (KT): 1, 10, and 100 tM (A.S. Janssen Biotech
N.y. R41400)
( Dissolve in I N hydrochloric acid (HCL) (Sigma H-7020)
V Filter with puradiscTM 25 (Whatman 6780-2502)159
KT: radiolabeled 1tCi 3H/O.5 mL of test solution (American
Radiolabeled, Inc. St. Louis, MS, ART794) (1 mCi/mL) (specific activity:
5 Ci/mmol)
NADPH-generating system Final concentrations
Vglucose-6-phosphate (G-6-P) (Sigma G-7250) 1.25 mM
Vglucose-6-phosphate dehydrogenase (1000 units/mL) 20 units/mL
(G-6-P DH) (Sigma G-5760)
VNADP (Sigma N-1630)
0.6 M and 0.9 M trichioroacetic acid (TCA)
(Sigma T-639, Fisher A322-100)
80 % methanol (MEOH) (GC Resolv A457-4)
I N sodium hydroxide (NAOH) (Malinckrodt 7708un1823)
Scintillation fluid (ICN CytoScintTM 882453)
Instructions
Conduct experiments on ice (4C) at all times.
Incubation solutionpipet into disposable glass vials (1 1X75 cm):
1.1 M potassium phosphate buffer (pH 7.4).
2. 1,10 or 100 1M KT (individual experiments).
3. 2 tCi/mL radiolabeled KT (3H-KT).
0.25 mM
4. 0.250 or 0.5 or 1 mg/mL microsomes (individual experiments).160
5. NADPH-generating system: (1.25 mM G-6-P, 20 units/mL G-6-P DH,
and 0.25 mM NADP)
6. Place in water bath with shaker at 37 C for individual time points.
7. Place on ice and pipet in 0.9 mL of 0.9 TCA, vortex.
8. Transfer to 2 mL eppendorf® vials, centrifuge 10 minutes at 14,000
rpm, discard supernatant.
9. Pipet in 1.2 mL 0.6 TCA, vortex, centrifuge at 14,000 rpm to 10
minutes, discard supernatant. Repeat this procedure a minimum of 4
times, except keep the supematant from the last time. Pipet
supernatant into another eppendorf® and take radioactive reading to
determine if background levels have been reached (< 100
disintegrations per minute (dpm)), if still too high repeat procedure
until background levels are obtained.
10. Into sample pellet pipet 0.5 mL 1.0 N NAOH, vortex.
ii. Heat in over at 60 C for a minimum of 45 minutes or until dissolved.
12. Pipet 0.300 mL of sample into scintillation vials (0.7 mL) containing
2.75 mL scintillation fluid with added glacial acetic acid (3 mL/200 mL
scintillation fluid).
13. Place in scintillation counter and take reading.161
PROTOCOL F
Complete MEDIA for epithelial intestinal-CCL241 cell line
Objective: Preparation of media for nutritional supplement for growth of the
intestinal epithelial cell line CCL24I for future analysis of the presence of the
flavin-containing monooxygenase enzyme (FMO). When working with celi lines
the area must be kept sterile and media must be filtered (acrocap-Pa114480). All
cell work was conducted in water-jacketed incubators Nuaire Biological Safety
Cabinets, Class II Type AIB3 (Model 1425-600).
Complete Media:
Dulbecco's Modified Eagle Medium (DMEM) (GibcoBRL 23700-024) powdered
dissolved and to the incomplete solution add:
V Fetal Bovine Serum (20%) (Summit FP-200-05)
V Sodium pyruvate (1:100 final concentration) (Sigma S-2770)
V Antibiotic/antimycotic solution (1:100 final concentration) (Sigma
A-9909): Solution contents in 100 mL: streptomycin (10 mg/mL),
penicillin G (10,000 Units/mL), amphotericin B (25 tg/mL)
V MEM non-essential amino acids 10 mM (final concentration 1:100)
(GibcoBRLl 114050)
V Oxaloacetic acid (final concentration 1:100) (Sigma 07753)162
v'Insulin (final concentration 0.2 Units/mL) mix in double distilled
water and added hydrochloride (HCL) (Sigma H7020) to complete
the dissolving (Sigma 1-500)
.Cell line CCL241 (American Type Culture Collection (ATCC))163
PROTOCOL G
Epithelial colon-CRL179O cell seeding and complete media
Objective: Preparation of plating and growth media for the epithelial colon-
CRLI 790 cell line for future analysis of the presence of the flavin-containing
monooxygenase enzyme. The CRL 1790 cells are required to be plated before
addition of growing media is added when starting cells as well as when splitting
cells into new flasks. Pipet plating media into new flasks and incubate at least 2
hours before adding cells. When working with cell lines, the area must be kept
sterile and media must be filtered (acrocap-Pal14480). All cell work was conducted
in water-jacketed Nuaire Biological Safety Cabinets, Class TI Type A/B3 (Model
1425-600).
Seeding (plating) media:
Dulbecco's Modified Eagle Medium (DMEM)/ F-12 (Ham) (GibcoBRL 12400-
016) incomplete (without growing nutrients) media powder dissolved in double
distilled water (dds) (Barnstead/thermolyne D7411 EasyPure UF). Final pH
between 7.2 7.4. Per 100 mL add:
/ Fibronectin0.598 mL of 0.167 mg/mL human u-Chymotryptic
120K fragment (GibcoBRL 12159-018)
V'Bovine serum albumin 50 tL of 0.00 1 mg/mL (Sigma A-4503)164
VVitrogen (purified collagen)100 p1 of 0.003 mg/mL (Cohesion
Tech C100828)
Pipet 14 mL into 75cm2(Costar 0.2 M vented cap, #3376) or 20 mL into
162cm2flasks (Costar 0.2 tM vented cap 3151). See illustration, Figure
1 a for cell growing chamber or flask.
Cell growing flask
Figure la: Schematic portrayal of cell incubation flask. (25, 75, or 162cm2)
Incubate for 24 hours. After the designated period of time aspirate plating
media and add complete media.
Complete media:
Aspirate old media and add new complete media every 3 days for normal feeding
after 24 hour seeding time period. Dissolve Dulbecco's F-12 (Ham) media powder
in dds. Final pH should be between 7.27.4. Per 500 mL:V Insulin (Sigma 1-6634)
V Apo-transferrin (Sigma T-2036)
V Epidermal growth factor (GibcoBRL53003-0 18)
isolated from male mouse submaxillary glands
V Phosphorylethanolamine (Sigma P-0503)(10 mM)
V Triiodothyronine (Sigma T-2877)
(dissolved with NaOH)
V Ethanolamine (Sigma E-0135)
V Bovine Albumin (Sigma A-4503)
V Hepes (Sigma H-3375)
V Sodium pyruvate (Sigma S-2770)
V Sodium selenite (Sigma S-526 1)
V Hydrocortisone (Sigma H-4881)
V L-glutamic acid (Sigma G-5638)
V NaOH (Mallinckrodt 7708un1823) pHto 7.27.4
165
Final
0.02 mglmL
0.128 pM
0.001 tg/mL
0.01 mM
0.0001 nM
0.01 mM
ig
10mM
0.5 mM
25 nM
50 nM
0.002 M
V Antibiotic/antimycotic solution (Sigma A-9909): 1:100 (final)
(Solution contents in 100 mL: streptomycin (10 mg/mL), penicillin
G (10,000 Units/mL), amphotericin B (25 tg/mL)
Cell line CRL179O (American Type Culture Collection (ATCC))T1tiIE)
Media for Caco-2 (HTB-37) cells
166
Objective: Preparation of media for growth of the Caco-2 (HTB-37) cell line for
analysis of the presence of the flavin-containingmonooxygenase enzyme.
MEDIA:
Dulbecco's Modified Eagle Medium (DMEM) (GibcoBRL 23700-024). Final pH
7.2 7.4. To DMEM add:
V Fetal Bovine Serum (FBS) (final concentration10%) (Summit FP-200-05)
V Sodium pyruvate (final concentration 1:100) (SigmaS-2770)
V MEM Non-essential amino acids (finalconcentration 1:100)
(GibcoBRLl 114050)
V Antibiotic/antimycotic solution (final concentration1:100) (Sigma A-
9909): Solution contents in 100 mL: streptomycin (10 mglmL),
penicillin G (10,000 Units/mL), amphotericin B (25g/mL)
HTB-37 (American Type Cell Culture (ATCC))167
PROTOCOL I
Procedure for seeding, trypsinizing, or freezing cell lines
Objective: The following procedure is to start a cell line, continue growth after
confluency for continued passage (replating), or for freezing for future use. Sterile
conditions should be utilized therefore procedure should be conducted in a laminar
hood or equivalent and wearing gloves for contamination-free as well as for
protection.
A.Prepare complete growing media for individual cell lines (Protocol F, G,
or H) Warm in water bath at 37 C prior to use: (Precision, ES722)
Complete growing media for selected cell line
Dulbecco's phosphate buffered saline (PBS) Ca, Mgfree
(GibcoBRL 14090-144)
50 mL aliquot of trypsin-EDTA (GibcoBRL25200-072) thawed at
room temperature
B.Trypsinize and reseed:
Remove cells from incubator (Cascade Scientific 2700/2700E),
aspirate cell culture medium, add PBS covering cells, shake to
remove debris and aspirate, and repeat 3X.
Add trypsin-EDTA covering cells. Wait for a few seconds and
remove all but a couple of drops.utsr.1
Incubate at 37 C for 5 10 minutes. Terminate trypsin with the
addition of warm complete media (Protocol F, G, or H).
Pipet into new flasks evenly increasing the number of flasks by 3 to
6, dependent upon the number of cells for distribution. Return to
incubator and grow at 37 ° C with 5%Co2.
C. Freezing cells:
Follow above procedure to trypsinize cells for detachment and
resuspend in growing media (Protocol F, G, or H)
Pipet into equal volumes into 15 mL centrifuge tubes. Centrifuge at
300400 rpm for 5 minutes. Aspirate supernatant carefully and
resuspend in 23 mL of the following 100 mL volume of freezing
media.
a.7.5 mL dimethyl sulfoxide (DMSO) (Sigma D-8779)
b.30.0 mL fetal bovine serum (FBS) (30%) (Summit FP-200-05)
c.62.5 mL Dulbecco's Modified Eagle Medium (DMEM) only
without added growth factors (incomplete)
Pipet l.Ox 106 cells determined by hemocytometry into individual I
cryogenic vials ( Nalgene® Company, 5000-0020), freeze for 1 hour
at 20C. Move to 80 C for 24 hours, then store in liquid nitrogen
Dispose of all used disposable items in biohazard bags and autoclave
for disposal. Clean all glassware with 10% bleach and soap.169
PROTOCOL J
Microsomal preparation from cell culture
Objective:To prepare microsomes from cell lines for future analysis of the
presence of the flavin-containing monooxygenase enzyme with western blotting
procedure (Protocol L).
Equipment
. 500 mL beaker for biohazard waste
Pipette-Aid® 263 (Drummond Scientific Co., Broomall, PA)
Homogenizer (ESGE Bio-homogenizer- M133/1281-0)
Cell scraper (25 cm) (Fisher Scientific 08-773-2)
Centrifuge (Beckman J2-HS, rotor JA-17)
Ultracentrifuge (L8-70M, rotor J42-1)
Reagents
Dulbecco's Phosphate Buffer Saline (PBS) Ca/Mg Free
(GibcoBRL 14090-144)
Homogenization Buffer
s/ mM trizma or trizmahydrochloride (Sigma T7-149)
/ 1 mM sodium ethylenediaminetetraacetic acid (EDTA)
(Sigma E-5134)
/ 250 mM Sucrose (Sigma S-7-903)170
V bring to volume with double distilledwater (dds)
(Barnstead/thermolyne D741 1 Easypure UF)
Add protease inhibitors to homogenization buffer:
Final
V 1 mL of 10 mlvi phenylmethylsulfonyl fluoride (PMSF) 0.25
mM
(Sigma #P-7626)
V 0.25 mL protease inhibitor cocktail, (Sigma #P-8340)
O.25/2OmL
V 0.5 mL trypsin inhibitor (Sigma #T-6522) 10 mgI2O
mL
V 0.5 mL of 10 mM 4-amidinophenylmethanesulfonyl fluoride0.25 mM
(APMSF) (Sigma #A-6664)
V 0.5 mL of 9.1 mM Pepstatin A (P-5318 Sigma) 0.228
mM
Resuspension buffer solution (pH 7.5), qs dds
V 10 mM trizma or trizmahydrochloride
V 1mMEDTA
V 20% glycerol (Fisher Biotech 56-81-5)
Coomassie® Plus Protein Assay (Pierce 23236)171
Instructions
1.Prepare mixture of protease inhibitors by adding 20 mL ice cold of
homogenization buffer, 1 mL PMSF, 0.25 mL protease inhibitor
cocktail, 0.5 mL trypsin inhibitor, 0.5 mL APMSF, and 0.5 mL
pepstatin A with dimethyl sulfoxide (DMSO) (Sigma D-8779) into a 50
mL centrifuge tube made the day of microsomal preparation.
2. Take one flask and discard medium, wash flask 3X with 37 C PBS.
Repeat with the second flask.
3. Add 2 mL of the protease mixture to each flask. Add 2 mL of ice-cold
homogenizing buffer, dislodge cells, and place both flasks on ice tilted
so that cells rest in back of flask bathed in homogenizing buffer. Let
flasks sit on ice for 5 to 10 minutes. (This part of the procedure can be
done with as many flasks as you can handle at one time).
4. Wash the sides of the flask using a pipette to ensure all cells are
suspended in solution. Transfer this solution to the second flask
5.Repeat this procedure with the remaining flasks.
If necessary, 2 mL of the protease mixture can be used to wash the
original flask. This solution can be transferred in a stepwise fashion to
subsequent flasks to ensure that a majority of the cells are suspended in
the final flask.
7.All tubes and working materials for making microsomes should be kept
cold. Keep everything on ice.172
8. The cell suspension in the final flask should be divided equally into two
50 mL centrifuge tubes on ice. Observe by microscope a small portion
of the cell suspension to see if the cell walls have been lysed, by using
the trypan blue exclusion test (Sigma T-8 154). If not, a small
homogenizer tube and plunger should be used to homogenize the cells.
Observe after homogenization to make sure the cells are lysed.
9.Centrifuge set at 4
0C at 4,000 rpm (2.2K*g) for 5 minutes to pellet
down. This is a suspension.
Microsomal preparation:
1.Second low-spin centrifuge step. Run the supernatant at 4
0C at 8,000
rpm (9K*g) for 5-10 minutes to pellet again. Keep supematant.
2.The final spin was conducted using an ultracentrifuge. Temp: 4 ° C;
Time: 90 minutes; Speed: 30,000 rpm (100,000 g).
3. When the cells have been pelleted, discard the cytosol (supernatant),
add a minute volume of resuspension buffer (-0.5 mL) to create a
suspension in one tube, transfer this suspension to as many tubes used
to create a suspension of all of the pelleted microsomes, until a final
suspension occupies the last tube. The final preparation should be
transferred to cryogenic vials (Nalgene® Company, 5000-0020).
Determine protein concentration.
4.Flash-freeze and store at 80
0C.173
PROTOCOL K
Microsomal preparation from donor tissue of human duodenum/jejunum
(Luetal., 1998)
Objective: To prepare microsomes from donor tissue for analysis of thepresence
of the flavin-containing monooxygenase enzyme for determinations by western
blot analysis. Human samples are considered biohazard waste. Double glove for
entire process of microsomal preparation. All cell work should be conducted in
Nuaire Biological Safety Cabinets, Class II Type A/B3 (Model 1425-600).
Equipment:
ice, cloth material with ice and place glass tray on top
small thick glass pieces for scraping
.homogenizer (ESGE Bio-homogenizerM133/1281-0) (Biospec
Products, Inc.)
sonicator dismembrator (Fisher Scientificmodel 100)
surgical tools: Long tweezers, scissors
biohazard waste container
centrifuge (Beckman J2-HS, rotor JAI7)
ultracentrifuge (Beckman L8-70M, rotor J42. 1).
cryogenic vials (Nalgene® Company, 5000-020)174
Reagents:
Homogenization buffer (bring to volume with double distilled water (dds))
V 100 mM potassium phosphate, pH 7.4 (Fisher P250-500)
V 1 mM sodium ethylenediaminetetraacetic acid (EDTA)
(Sigma E-5134)
V 150 mM potassium chloride (Sigma P-9541)
V 0.1 mM dithiothreitol (Fisher Biotech BP172-5)
V 250 mMsucrose (Sigma S-2378)
Acid these inhibitors the day of process to homogenization buffer:
(Gobinet-Georges, 2000; Kelly and Struthers, 2001)
V pepstatin A (Sigma P-5318)
Final
0.228 mM
V trypsin inhibitor (Sigma T-6522) 10 mg/20 mL
V 4-amidinophenylmethanesulfonyl fluoride(APMSF) 0.25 mM
(Sigma A-6664)
V phenylmethylsulfonyl fluoride (PMSF) (Sigma P-7626)0.25 mM
V protease inhibitor cocktail (SigmaP-8340) 0.25 mLI2O mL
V aprotinin (Fisher BP2503 10) (activity: 10,980 kallikrein
inhibitory units (KIU/mL) 4000 KIU/total vol
(100 mL of total volume of homogenization buffer will accommodate 25g of raw
tissue plus 5.6 g of already prepared mucosal tissue).Other reagents: Final
175
tetrasodium pyrophosphate pH 7.4 (Sigma P-8010) 100 mM
.Coomassie® Plus Protein Assay (Pierce 23236)
Instructions:
1. Remove the upper villus layer of the mucosa with edge of a glass slide
or razor blade.
2. Weigh before suspending in homogenizaton buffer.
3.Suspend the mucosal cells in cold homogenization buffer.
4.Pellet mucosal cellscentrifuge at 5,000 rpm (3,440 g) for 6 minutes at
4°C.
5. Wash with 100 mM potassium phosphate homogenization buffer.
6. Homogenize in a 4-fold (by pellet weight) volume of homogenization
buffer using hand homogenizer 10 strokes, if unable to homogenize,
use automatic homogenizer then sonicate for 10 sec at #3 setting with
sonic dismembrator.
7.Pellet homogenate at 9,500 rpm (12K*g) for 30 minutes at 4 °C.
8.Filter S9 supernatant through two to four layers of cheesecloth.
9.Pellet supernatant at 30,000 rpm (100K*g) in ultracentrifuge for 70
minutes, at 4 ° C.
10. Wash in minimal buffer volume containing:
a.100 mM tetrasodium pyrophosphate, pH 7.4176
b.1 mM sodium EDTA in homogenizer to remove hemoglobin
11. Pellet at 30,000 rpm (100K*g) for 15 minutes at 4C.
12. Resuspend microsomes in 100 mM potassium phosphate buffer (pH
7.4) containing: 250 mM sucrose and 1 mM EDTA.
13. Transfer to cryogenic vials, snap-freeze, store at80C,
14. Determine protein concentrations.PROTOCOL L
Western blot analysis
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Objective: To determine the presence of FMO protein presence within: the Caco-
2 (HTB-37) cell model; jejunum and duodenum microsomal preparations from
human donors; the epithelial cell lines of colon (CRL 1790) and intestine
(CCL24 1).
A) Preparation of Separating Gels:
Reagent Stock Solutions:
Buffer 1: To prepare 500 mL, pH 8.8,
90.85 g Tris Base (Fisher BP 152-5)
0.4% sodium dodecyl sulfate (SDS) (Fisher Biotech BP166-500)
Buffer 2: To prepare 100 mL, pH 6.8.
6 g Tris HCI (Sigma T-5941)
0.4% SDS
2 mg bromo blue dye (Fisher Biotech 11-39-9)
Running Buffer: To prepare 2 Liters
6gTrisBase
28.8 g glycine (Zaxis 9 10-9000457)
0.1% SDS
2X Sample Buffer: To prepare 10 mL,
3 g of urea (Zaxis 9 10-9000760)178
500 mg SDS
600 mg dithiothreitol (DTT) (FisherBiotech BP172-5)
50 mM Tris base (pH 8.0) (Fisher BP152-5)
1 mg bromophenol blue (1 mg/10 mL) (Fischer Biotech 115-39-9)
4X Sample Buffer: To prepare 10 /mL,
6 g of urea
1 g SDS
1.2gDTT
100 mM Tris base (pH 8.0)
I mg bromophenol blue (1 mg/I 0 mL)
Transblot Buffer: To prepare 4 liters,
12 g (final 25 mM) Tris base
59.6 g (final -192 mM) glycine
800 ml (final20%) MeOH (HPLC grade, Fisher A457-4)
Immunoblot Buffer: To prepare 2 liters,
4.84 g 20 mM Tris base, pH 7.2
58.44g 500 mM NaC1 (Fisher S-3014)
50% Glycerol: To prepare 20 mL,
10 mL glycerol (Fisher Biotech 56-81-5)
10 mL double distilled water (dds) (Barnstead/thermoloyne D71 1
EasyPure UF)
30% Acrylamide/0.8% bisacrylamide (B ioRad 161-0158)179
Store at 4 ° C for up to 6 months.
TEMED (BioRad 161-0800)
10% Ammonium persulfate (APS) (Zaxis 910-9110057)100 mg/mL:
(good for one week).
0.1% SDS 0.1%SDS 100 mL
2% Sodium Azide (Fisher Biotech BP9221-500): 2.0% Na-Azide 45 mL,
1.0% BSA (Sigma A-9909): 10 mg/mL
Chemiluminescence detection (BioRad immunostar 170-5012 and Amersham
Pharmacia Biotech ECL RPN2 106)
Molecular weights (MW) (BioRad 161-0324)
FMO 1, FMO3, FMO5 of human cDNA purified in a baculovirus system (Gentest,
A241, A243, A245, respectively)
For a SDS-PAGE separation gel, the following ingredients are needed for 2 small
gels:
15.0%12.5%10% 7.5% 6.0%
Buffer 1 6.0 mL6.0 mL6.0 mL 6.0 mL6.0 mL
Water 4.2 mL6.2 mL8.2 mL 10.2 mL11.4 mL
30%
Acrylamide
12 mL 10 mL8.0 mL 6.0 mL4.8 mL
50% 1.6 mL1.6 mL1.6 mL 1.6 mL1.6 mL
TEMED8 tL 8 tL 8 iL 8 iL 8 iL
APS 90 tL 90 tL 90 !LL 90 tL 90 !LNote: When TEMED and APS are added to mixture, the gel will start to solidify.
Pour mixture into gel casting system 10 X 10cm (Fisher Scientific, FB-GC1O-l)
and gently layer 0.1% SDS on top to flatten interface. Set for 2 hours.
Procedures for the preparation of the SDS-PAGE gel:
1. Wipe glass plates with ethanol, (Kim Wipes).
2.Arrange plastic spacers between metal and glass plate. Put the set inside a
plastic bag.
3.Put the plates (inside the bag) on the stand in the proper place.
4.Align with white spacer card. Card should fit loose, secure mold and
remove card.
5. Mark the level of gel that we will pour gel up to this level. In this case,
4.5 cm from the bottom of the plate will be marked. The MW of FMOs
is about 50-65 Dalton (Da); thus, FMOs will be in the middle of a 10%
separating gel.
6.Prepare APS 10%, vortex, label, and store at 4 ° C.
7. Mix components. Pour the gel between the plates up to the level marked.
Pipette 1 mL of 0.1% SDS on top of the separating gel to flatten the
interface of the gel. This gel needs to set for 2 hours or it can be kept in
refrigerator for 1 week at 4C. If the gel is to be stored away for later
use, tape down the plastic bag until ready to use.181
B) Components and procedures for stacking (loading) gels preparation.
For Stacking Gels, the following ingredientsare needed for 2 small gels:
Buffer2 3.75mL
Water 9.75 mL
30% Acrylamide 1.50 mL
TEMED 8 tL
APS 0.l5OmL
Procedures for the preparation of stacking (loading) gels
1.After the resolving gel has solidified, pour off the 0.1% SDS.
2. Mix components for stacking gels.
3.Pipette the stacking gel mixture on top of the separating gel and insert combs
into the gels. Thick style (12 mm)10 loading spaces. (Fisher FB ECI29B)
4.Solidifies in approximately 30 mm.
Prepare microsomal samples.
1.Prepare samples including molecular weights (MW) and purified
proteins by adding 15 d of 4X loading buffer, desired protein
concentration, and re-suspension buffer for a total volume of 60 tL.
2.Vortex, place samples on boiler (-400 ° C) for 2 3 minutes, re-ice, and
vortex.182
3.Set-up and run SDS-PAGE gels. For 2 gels. Fill inner chamber with
running buffer to the level above the inner glass plates and check for
leaks. Fill catch basin half way with running buffer.
Procedures for loading and running samples
1.After the running time, separate the gel plates and discard the stacking gel.
2.Nick the upper right corner ofone of the gels, if running two to identify
later.
3.Soak the gel in transblot buffer for 20 mm.
4. Assemble the gel sandwich into transfer apparatus (CBS Scientific Company,
Inc., EBU-202, Del Mar, CA) with a nitroceflulose (BioRad 162-0115)or
polyvinyliden difluoride (PVDF) (ImmobilonTM-P, IPVH00001O) membrane
and chromotography paper (Whatman 3mm, 3030690),pre wet in transhiot
buffer in the following order from top to bottom:
******************White side support******************
Foam pad
1 sheet of Whatman paper (CN#303-690)
Membrane
GEL
1 sheet of Whatman paper
Foam pad
******************Black side support******
Load the gel sandwich in the transblot cell with the black support facing the
negative plate (black) and the red support facing the positive plate (red) and
add ice to opaque white container for mini-gels andrun transblot 100 volts for
1 hour.183
C) Blocking and washing for enchanced chemiluminescence detection for
nitrocellulose or PVDF membranes.
1.Remove the membrane and gel from transblot sandwich and cut the upper
right edge of membrane even with the gel for marker.
2.Lift off the gel and check that pre-stained MW standards (BioRad #16 1-
0324) have transferred to nitroceflulose.
Procedure for blocking, incubation, and washing for NITROCELLULOSE
1.Air-dry the nitrocellulose briefly.
2.Block the nitrocellulose with immunoblot buffer (IB) + 3% BSA for 30
mmat room temperature on rotating shaker (Labline Rotator, Model 1314)
at room temperature (RT) (setting # 4).
3.Pour off blocking buffer and add -.20 mL of diluted primary antibody
(Gentest A241). Dilute primary antibody to desired concentration in lB +
1% BSA 1:5001:1000 dilution of polyclonal sera. Incubate
nitrocellulose membrane with primary antibody overnight on rotating
shaker at RT (setting #4).
4. Wash the membrane with 2 changes of TB + 0.05% Tween-20 (TW20-IB)
(Fisher BP337-100) and 1 change of TB without Tween-20 for 20 minutes
each wash on rotating shaker at RT (setting #4).
5.Incubate with secondary antibody at desired concentration of (BioRad
#170-65 18) goat anti-rabbit IgG (H +L)-alkaline phosphatases (Ap)
conjugate in TB + 1% BSA for 1 hour on rotating shaker at RT (setting #4).6.After incubation time, remove the secondary antibody and save for later
use by adding 0.2% Na-azide at 4
°C.
7. Wash nitrocellulose for a total of 5 washes. Wash with 4 changes of
immunoblot buffer + 0.05% TW2O-IB solution at 20 minutes each wash.
Wash once with lB for 20 minutes on rotating shaker at RT (setting #4).
Procedure for blocking, incubation, and washing for PVDF membrane
1.Rinse PVDF membrane in TB briefly (15 seconds)
2.Rinse membrane in MEOH (Fisher A457-4) briefly (15 seconds)
3.Place on chromotography paperair dry 20 minute or more
4.Place in plastic bag sealed stored at 4 °C until exposure.
5.Primary incubationsubmerge PVDF membrane in MEOH (15 seconds)
6.Submerge into lB (15 seconds)
7. Block in lB with 2% or to desired concentration of powdered milk
(Safeway nonfat dry milk) for 30 minutes at room temperature on rotating
shaker at room temperature (setting #4).
8.Pour off blocking buffer in the sink and add 20 mL of diluted primary
antibody to membrane. (Dilute primary antibody to desire concentration in
TB + 0.5% powdered milk generally 1:500 1:1000 dilution of polyclonal
sera).
9.Incubate PVDF with primary antibody 4 hours on rotating shaker at RT
(setting #4).185
10. Wash the membrane with 2 changes of immunoblot buffer+ 0.05% TW2O-
TB and 1 change of 113 without Tween-20 for 10 minutes each washon
rotating shaker at room temperature (setting #4).
11. Incubate with secondary antibody (Gentest 458241) of goat anti-rabbit IgG
(H +L)-horseradish peroxidase (Hrp) conjugate in lB + 0.5% powdered
milk for 1 hour on rotating shaker at RT (setting #4).
12. Wash membrane for a total of 3 washes. Wash with 2 changes of lB buffer
+ 0.05% TW2O-IB solution for 10 minutes each wash. Lastly, wash
once with lB for 10 minutes on rotating shaker at room temperature
(setting #4).
D) Development of membrane.
Items needed for film developing:
Film (Kodak Sigma F-1274)
Exposure cassette (Sigma E-8510)
Developer and fixer (Fisher Scientific 05-728 104)
Acetic Acid, glacial (Fisher Scientific A35 500)
Chemiluminescence
Instructions for development by chemiluminescence
1. Briefly, blot-dry the membrane and place the membraneon a piece of Saran
plastic wrap (enough to fold over and cover the membrane).
2. Prepare the Bio-Rad Immune-Star Substrate Pack (170-5012) immunoblotsubstrate by adding 2 mL Immun-Star substrate (170-5018) + Immuno Star
enhancer 100 1tL (170-5019) for AP or prepare Amersham Pharmacia
Biotech ECL reagent for Hrp mixing a 1:1 ratio(RPN2 106).Vortex.
3. Pour enhancer substrate mixture onto the membrane.
4. Pour excess solution off onto a paper towel andwrap membrane with plastic.
5. Place wrapped membrane into the exposure cassette.
6. Develop film in dark room. (Exposure times variable)
The following figure, Figure 25 isa depiction of the minigel electrophoresis
apparatus.187
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Figure ib: Schematic drawing of the minigel electrophoresis apparatus.ir
PROTOCOL M
Immunoprecipitation and Western Blotting
Objective: Immunoprecipitation was utilized to forman antibody-antigen
complex for determination of the presence of the flavin-containing
monooxygenase enzyme. Immunoprecipitation in conjunction with western
blotting takes three days to complete the analysis.
Samples - Microsomal preparations from cell culture
Equipment
Rotary platform (in house apparatus)
Centrifuge (Eppendorf 5415C)
Reagents
FMO 1, FMO3, FMO5 from human cDNA purified in a baculovirus system
(Gentest A241, A243, A245).
Homogenization buffer (pH 7.4):
V'100 mM trizma (Sigma T-7-149)
V250 mM sucrose (Sigma S-7-903)
V 1 mM ethylenediaminetetraacetic acid (EDTA) (Sigma E-5134)
Add to 100 mL of homogenization buier:
V 2.5% Triton X-100 (2.5 mL) (Sigma X-100)
V 50 uL (0.2%) Protease Inhibitor Cocktail (Sigma#P-8340)Day 1
1.Obtain microsomal samples from 80 C freezer. Be sure to keep samples
on ice. Determine protein concentration for each sample.
2.Dilute samples (300 tg) with 0.5 mL 2.5% Triton dilution/homogenization
buffer.
3.Tumble mixture using a rotary platform for 1 hour at 4 ° C.
4.Incubate supernatant with a 1:500 dilution of primary antibody overnight at
4 ° C using tumbler (2 tL of stock FMO- 1 or FMO-3 or FMO-5 primary
antibody).
Day 2
1.For the last hour, add 50 L of the 50% slurry (75 mg PAS/0.6 mL
homogenization buffer) of Protein A Sepharose (PAS) to each sample and
incubate at 4
0
NOTE- Before incubation with samples: The stabilizers are sugars
(dextran and lactose), therefore the homogenization buffer can be used to
dissolve and remove the sugars and leave the PAS in tact. Use equal
amounts of homogenizing buffer and PAS, vortex briefly, and centrifuge
at 14,000 rpm for 15 seconds to pull down beads. Remove supernatant.
Repeat this procedure 3 times. Soak and swell the PAS with
homogenization buffer for a minimum of half-hour at room temperature in
eppendorf® tube.190
2.Centrifuge samples (table-top centrifuge) at 14,000 rpm for 30 seconds to
8 minutes, or until a pellet is obtained. (Freeze the centrifuge rotor for 15
minutes prior to loading to keep samples cool). Pipette off supernatant.
3. Wash each sample pellet 4 times with an equal volume (- lmL) of 2.5%
triton Dilution! homogenization buffer. II is difficult to see the pellet for,
therefore centrifuge samples briefly following each wash to be sure the
pellet is forced to the bottom to avoid pipetting off the pellet along with
the supernatant.
4. Wash 2 times with homogenization buffer without detergent. Pipette off
supernatant following each wash arid save.
5.Follow western protocol for sample preparation, resolve, and expose to
primary antibody overnight (Protocol L), except for sample preparation
boil 2 3 minutes, centrifuge to create pellet and load supernatant.